Int.J.Curr.Microbiol.App.Sci (2025) *14*(11): 101-134

International Journal of Current Microbiology and Applied Sciences
***ISSN: 2319-7706* Volume 14 Number 11 (2025)**
Journal homepage: http://www.ijcmas.com

Review Article https://doi.org/10.20546/ijcmas.2025.1411.012

SARS-CoV-2: A Comprehensive Review of its Biology, Immunity, and Therapeutic Solutions

Bhanupratap Vishwakarma[1*], Harshada Kulaye[2], Shruti Tiwari[1], Shizan Alam[3], Shivani Pandey[1] and Sonali Joshi[1]

[1]Department of Microbiology, ZSCT's Thakur Shyamnarayan Degree College, Kandivali Mumbai- 4000101, India
[2]Department of Microbiology, Kishichand Chellaram College, Mumbai-400020, India
[3]Department of Microbiology, Guru Nanak Khalsa College of Arts, Science and Commerce, Dadar, Mumbai -400019, India

**Corresponding author*

Keywords

SARS-CoV-2, COVID-19, Viral structure, Spike protein, ACE2 receptor, Immune evasion, Antiviral therapies, Monoclonal antibodies, Vaccine efficacy, Variants of concern.

Article Info

Received:
08 September 2025
Accepted:
20 October 2025
Available Online:
10 November 2025

A B S T R A C T

The global emergence of SARS-CoV-2 has led to an unprecedented health crisis, underscoring the critical importance of understanding its biology to inform control measures, immunity, and treatment approaches. This review explores the virus's structural and genomic characteristics, including the spike protein and mechanisms of host cell entry, and compares SARS-CoV-2 with related coronaviruses, SARS-CoV and MERS-CoV. An analysis of transmission dynamics highlights factors such as viral load, routes of exposure, and host susceptibility, which together shape the virus's spread. We further examine the pathogenesis of SARS-CoV-2, detailing its replication cycle, host-pathogen interactions, and impact on multiple organ systems. The immune response to SARS-CoV-2 is assessed through both innate and adaptive mechanisms, shedding light on immune evasion strategies and implications for long-term immunity. The role of immune memory and the potential for reinfection are discussed in the context of emerging viral variants, which pose challenges to vaccine efficacy and herd immunity efforts. This review also covers therapeutic strategies, including antiviral drugs, immunomodulators, and vaccines, alongside promising new treatments under investigation. Finally, we address challenges in SARS-CoV-2 research and propose directions for future studies, emphasizing the lessons learned from this pandemic to enhance preparedness for future outbreaks. Through a comprehensive synthesis of current knowledge, this review aims to contribute to the ongoing efforts to mitigate SARS-CoV-2's impact on global health.

Introduction

The emergence of SARS-CoV-2, the novel coronavirus responsible for COVID-19, marked a profound shift in global public health. First identified in Wuhan, China, in December 2019, the virus quickly spread, leading to an unprecedented health crisis as it swept across continents within weeks. Its rapid transmission, fuelled by respiratory droplets and aerosols, allowed SARS-CoV-2 to reach pandemic status early in 2020. Unlike many other viruses, SARSCoV-2 poses unique challenges, as it infects individuals across all age groups, causes a wide range of symptoms, and can spread from asymptomatic carriers. This silent transmission dynamic, combined with high contagion rates, overwhelmed public health systems worldwide, leaving healthcare providers and researchers scrambling to respond (1).

COVID-19, the disease caused by SARS-CoV-2, manifests in diverse ways, from mild upper respiratory symptoms to severe respiratory distress and multi-organ failure in critical cases. This variability in disease severity has presented challenges for both diagnosis and treatment. Compounding these difficulties, SARS-CoV-2's ability to mutate has led to the emergence of several variants with varying degrees of transmissibility, immune escape, and virulence (2). Some of these variants, like Delta and Omicron, have caused significant resurgences of COVID-19, sometimes despite high vaccination coverage. The ongoing evolution of these variants has underscored the need for adaptive responses in both public health policies and medical interventions. Beyond the immediate toll on health, SARS-CoV-2 has created a far-reaching socioeconomic impact, triggering widespread job losses, disrupting education systems, and altering social interactions. Lockdowns, quarantines, and travel restrictions became common strategies, affecting daily life on a global scale. Meanwhile, public health infrastructure faced significant strain, exposing vulnerabilities in healthcare readiness, supply chains, and the availability of critical resources, such as personal protective equipment (PPE) and ventilators (3).

This unprecedented pandemic has highlighted the need for a deep understanding of SARS-CoV2's biology how it infects cells, evades immune defences, and impacts various systems within the body. Research into the virus's molecular and cellular mechanisms, as well as its interaction with the human immune system, remains crucial for developing targeted therapies and preventive measures (4). By exploring SARS-CoV-2's transmission dynamics and pathogenicity, we gain insights that are essential not only for managing the current crisis but also for enhancing preparedness for future outbreaks. Understanding this complex biology will be fundamental in guiding both immediate responses and long-term public health strategies, making it a critical area of study in virology and infectious disease management (5). Understanding the biology of SARSCoV-2 is crucial for effectively managing and controlling the COVID-19 pandemic, as it provides insights into how the virus infects and interacts with human cells, how it spreads among people, and how it triggers immune responses. This knowledge forms the foundation for designing strategies to reduce transmission, developing targeted treatments, and creating vaccines that can elicit strong and lasting immune responses. Advances in understanding SARS-CoV-2's biology have greatly informed public health strategies to curb its spread. Recognizing respiratory droplets and aerosols as primary transmission routes led to guidance on mask-wearing, social distancing, and ventilation improvements, particularly in crowded or confined spaces (6). Additionally, insights into viral shedding and the potential for asymptomatic transmission have emphasized the importance of testing, contact tracing, and isolating cases to mitigate unnoticed spread. The virus's capacity for mutation has been crucial In pandemic management, as monitoring variants allows adjustments to vaccines and treatments. For instance, updated vaccines target new variants to retain efficacy. Knowledge of SARS-CoV-2's impact on the immune system has also improved treatment for severe cases, particularly those involving "cytokine storms," by utilizing anti-inflammatory drugs like corticosteroids to manage inflammation. In essence, understanding SARS-CoV-2's biology underpins tailored, adaptable responses to COVID-19 and serves as a foundation for managing similar future outbreaks (7).

This review aims to examine the biological aspects of SARS-CoV-2, focusing on its transmission, immune interactions, and therapeutic strategies. By exploring how the virus spreads, evades immune defences, and responds to treatment, the review seeks to offer a thorough understanding of SARS-CoV-2's impact and the measures required to control it. First, it will detail transmission mechanisms, such as viral shedding and aerosol spread, to identify effective prevention methods and understand the virus's widespread reach. The review will then analyse the immune response, covering both innate and adaptive reactions, while explaining how

SARS-CoV-2 can evade detection and, in severe cases, induce excessive inflammation. Insights into these immune processes are vital for advancing vaccines and treatments that can support immune defences or prevent overreactions. Finally, the review will assess current and emerging treatments, including antiviral drugs, monoclonal antibodies, and vaccines, highlighting approaches that target viral entry, replication, and inflammation. This comprehensive review bridges core viral biology with practical strategies, serving as a valuable resource for researchers, healthcare professionals, and policymakers.

Viral Structure and Genome

Structure of SARS-CoV-2: SARS-CoV-2, like other coronaviruses, has a distinctive and highly organized structure that is integral to its infectivity and ability to cause disease. This virus is enclosed in a lipid membrane, or envelope, derived from the host cell during viral assembly, which acts as a barrier to protect the viral components. Within this structure, several specialized proteins interact to allow SARS-CoV-2 to attach to, enter, and replicate within host cells, while also evading the immune response. These proteins include the spike (S) protein, membrane (M) protein, envelope (E) protein, and Nucleocapsid (N) protein, each with unique roles in the viral life cycle and disease progression (8).

Spike (S) Protein: The spike (S) protein is arguably the most significant component for understanding SARS-CoV-2's infectivity. It is a large, trimeric protein that protrudes from the viral surface, giving coronaviruses their crown-like appearance. The spike protein's primary role is to mediate entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. This process is highly specific and effective, as the spike protein has evolved to attach to ACE2 with high affinity. The spike protein consists of two main subunits, S1 and S2, each with distinct functions in the infection process. The S1 subunit is responsible for recognizing and binding to the ACE2 receptor through its receptor-binding domain (RBD). Once the virus is bound to the ACE2 receptor, the S2 subunit undergoes a series of conformational changes, which enable the viral and cellular membranes to fuse, allowing the viral RNA to enter the host cell. This fusion process is essential for infection, making the spike protein a primary target for neutralizing antibodies and vaccines designed to block this interaction and prevent the virus from establishing an infection (9).

Nucleocapsid (N) Protein: Inside the viral envelope, SARS-CoV-2's RNA genome is packaged and protected by the Nucleocapsid (N) protein. This protein binds tightly to the viral RNA, creating a stable nucleocapsid complex that safeguards the genetic material until the virus enters a host cell. The N protein plays multiple roles beyond RNA packaging; it assists in RNA replication and assembly of new virions, ensuring that the viral genome is accurately replicated and efficiently incorporated into new virus particles. Additionally, the N protein interacts with the host cell's machinery, which may contribute to immune evasion by inhibiting cellular processes that would otherwise alert the immune system to the presence of the virus (10).

Membrane (M) Protein: The membrane (M) protein is the most abundant structural protein in

SARS-CoV-2, forming the viral envelope's backbone and maintaining its shape. Structurally, the M protein spans the lipid membrane and is believed to be responsible for the characteristic shape and stability of the viral envelope. The M protein plays a pivotal role in the assembly of new virions, as it interacts with other structural proteins, including the N and E proteins, to coordinate the encapsulation of the viral RNA.

This protein's role in maintaining structural integrity is crucial, as it ensures the stability and infectivity of the virus as it travels between hosts (11).

Envelope (E) Protein: Although present in smaller quantities, the envelope (E) protein is essential for the virus's life cycle and infectivity. This small protein has multiple functions that contribute to the efficient assembly, release, and spread of new viral particles. The E protein is involved in assembling viral components during replication and may play a role in viral budding, a process by which new virus particles exit the host cell. Some studies suggest that the E protein also has ion channel activity, which could impact the virus's interaction with the host immune response by modulating the cell's internal environment. Additionally, the E protein's interactions with host cell pathways may help SARS-CoV-2 dampen the immune response, making it more difficult for the host to detect and eliminate the virus (12).

Together, these structural proteins S, N, M, and E work in concert to enable SARS-CoV-2 to infect and propagate within human cells effectively. The spike protein initiates infection by attaching to ACE2, allowing the virus to enter the cell, while the N protein protects the RNA genome and facilitates replication within the cell. Meanwhile, the M protein provides structural support, and the E protein enhances viral assembly and release. This functional integration not only supports efficient infection and replication but also helps the virus evade the host immune system, allowing it to spread rapidly and cause disease. The complex organization of these proteins and their interactions with human cells highlight potential intervention points for therapies and vaccines. Targeting the spike protein to prevent entry, for example, has been the foundation of several vaccine platforms, while understanding the roles of the N, M, and E proteins may provide additional targets for antiviral therapies. By studying these structural proteins in detail, researchers gain valuable insights that inform ongoing efforts to control and mitigate SARS-CoV-2's impact.

Overview of the SARS-CoV-2 genome and key genes involved in infection and replication

The genome of SARS-CoV-2 is a single-stranded, positive-sense RNA molecule approximately 29,900 nucleotides in length, making it one of the largest RNA genomes known among viruses.

This RNA genome encodes for both structural and non-structural proteins, each playing crucial roles in the virus's ability to infect cells, replicate, and evade the immune response. The genome organization of SARS-CoV-2 is highly efficient, allowing it to produce the necessary proteins for its life cycle and rapid spread (13).

Genome Organization and Structure: The SARS-CoV-2 genome begins with two large open reading frames (ORFs), ORF1a and ORF1b, which occupy around two-thirds of the genome. These ORFs encode polyproteins that are subsequently cleaved into 16 non-structural proteins (NSPs), essential for viral replication, transcription, and immune evasion. The remaining one-third of the genome encodes structural proteins such as, spike (S), envelope (E), membrane (M), and nucleocapsid (N), and several accessory proteins that assist in the virus's pathogenicity and immune response modulation.

Key Genes and Proteins Involved in Infection and Replication

ORF1a and ORF1b-Non-Structural Proteins (NSPs): The first two-thirds of the genome, comprising ORF1a and ORF1b, encode a large polyprotein that is processed into 16 non-structural proteins (NSP1–NSP16) through proteolytic cleavage. These NSPs perform various functions critical for replication and immune evasion:

NSP3 and NSP5: These are viral proteases that cleave the polyprotein into individual functional NSPs. NSP3 (papain-like protease) and NSP5 (3CLpro or main protease) are essential for processing the viral polyprotein, making them key targets for antiviral drugs aiming to halt viral replication (14).

NSP12 (RNA-dependent RNA polymerase, RdRp): This enzyme is the central player in viral RNA replication and transcription. RdRp synthesizes new RNA strands using the viral RNA as a template, enabling the virus to replicate its genome and produce new viral particles (15).

NSP13 (Helicase): The helicase unwinds the viral RNA, facilitating replication and transcription. Its function is essential for ensuring efficient and accurate replication of the SARS-CoV-2 genome (16).

NSP14 (Exoribonuclease): NSP14 has proofreading activity, which is unusual for RNA viruses.

This exoribonuclease reduces the mutation rate by correcting errors during RNA synthesis, allowing SARS-CoV-2 to maintain its large genome more stably (17).

NSP1 and NSP16: These NSPs help the virus evade the immune system. NSP1 degrades host mRNA, impairing the host's ability to mount an immune response, while NSP16 modifies the viral RNA cap structure, helping it evade detection by host immune sensors (18).

Spike (S) Protein: The spike (S) protein gene encodes the large glycoprotein on the surface of SARS-CoV-2, which plays a pivotal role in initiating infection. The spike protein binds to the ACE2 receptor on human cells, allowing viral entry. This interaction is facilitated by the receptorbinding domain (RBD) on the S protein. Once bound to ACE2, the spike undergoes a structural change that enables membrane fusion and entry of the viral genome into the host cell. Given its essential role in

infection, the spike protein is the primary target for neutralizing antibodies and vaccines (9).

Envelope (E) Protein: Although it is one of the smallest structural proteins, the envelope (E) protein plays multiple roles in the virus's life cycle. It is involved in the assembly and release of viral particles from infected cells. Additionally, E protein has ion channel activity, which may contribute to its role in modifying the host cell environment to benefit viral replication and assembly. Research also suggests that E protein may play a role in pathogenicity by affecting the host immune response (12).

Membrane (M) Protein: The membrane (M) protein is the most abundant protein in the viral envelope and is essential for virus assembly and structural integrity. It interacts with other structural proteins, particularly the spike (S) and nucleocapsid (N) proteins, to form a stable viral particle. The M protein's role in the assembly process ensures that newly formed virions are properly structured and infectious (11).

Nucleocapsid (N) Protein: The nucleocapsid (N) protein binds to the viral RNA genome, forming a ribonucleoprotein complex that helps package and protect the RNA within the viral particle.

Beyond RNA binding, the N protein is involved in various stages of the replication cycle, including RNA synthesis and immune modulation. It helps in assembling new virus particles and may play a role in dampening the host immune response by interfering with cellular signaling pathways (10).

Accessory Proteins (ORF3, ORF6, ORF7, ORF8, etc.): SARS-CoV-2 also encodes several accessory proteins, such as ORF3a, ORF6, ORF7a, ORF8, and ORF10, which are not directly involved in viral replication but contribute to the virus's pathogenicity and immune evasion.

For example:

ORF3a: Linked to inflammatory responses and may contribute to cell death, thus enhancing the virus's ability to spread by damaging host tissues.

ORF6: Known to inhibit immune signalling pathways, such as interferon response, thereby reducing the host's antiviral defences.

ORF8: Believed to assist in immune evasion by down regulating MHC-I molecules, making it harder for the immune system to recognize and respond to infected cells (19).

Together, these genes and proteins create an efficient system that allows SARS-CoV-2 to infect human cells, replicate, and spread while minimizing immune detection. After binding and entering a host cell via the spike protein, the virus uses its non-structural proteins to replicate its RNA and produce new viral proteins. Structural proteins then assemble around the replicated RNA, forming new virus particles that are released to infect other cells. Understanding the roles of each gene and protein within the SARS-CoV-2 genome is essential for designing antiviral drugs, vaccines, and immune-based therapies. By targeting specific genes or proteins, researchers can disrupt the virus's life cycle at various points, offering multiple strategies to mitigate the impact of COVID-19 and prevent further spread.

Comparison with other coronaviruses (e.g., SARS-CoV, MERS-CoV)

SARS-CoV-2 shares many similarities with other coronaviruses, particularly SARS-CoV (the virus responsible for the 2002-2003 SARS outbreak) and MERS-CoV (the virus behind the 2012 Middle East Respiratory Syndrome outbreak). All three viruses belong to the Coronaviridae family and the Betacoronavirus genus, indicating a close evolutionary relationship and many shared structural and functional characteristics. However, important differences in their genetics, transmission dynamics, and pathogenicity have shaped the distinct clinical and epidemiological profiles of the diseases they cause (20).

Genetic and Structural Comparisons: The genomes of SARS-CoV-2, SARS-CoV, and MERSCoV are all positive-sense single-stranded RNA, with SARS-CoV-2's genome having around 80% similarity to SARS-CoV. This genetic overlap means that SARS-CoV-2 and SARS-CoV share many structural features and mechanisms of infection. However, MERS-CoV is more distantly related, sharing about 50% similarity with SARS-CoV-2, and it uses a different cellular receptor for entry, which influences its infectivity and spread. One of the most significant structural similarities among these viruses is the spike (S) protein, which allows them to attach to and enter human cells. For both SARS-CoV and SARS-CoV-2, this protein binds to the

angiotensinconverting enzyme 2 (ACE2) receptor on human cells. However, SARS-CoV-2's spike protein has evolved to have a higher binding affinity for ACE2, contributing to its greater transmissibility compared to SARS-CoV. This stronger affinity is partly due to a unique furin cleavage site in the spike protein of SARS-CoV-2, which is absent in SARS-CoV. MERS-CoV, on the other hand, uses a different receptor, dipeptidyl peptidase-4 (DPP4), which is thought to limit its ability to spread between humans as efficiently as SARS-CoV-2 (21).

Transmission Dynamics: SARS-CoV-2's ability to spread more efficiently than SARS-CoV or MERS-CoV has been a critical factor in the global scale of the COVID-19 pandemic. SARS-CoV2 has a longer asymptomatic period during which infected individuals can unknowingly transmit the virus, allowing it to spread widely within communities before symptoms develop. In contrast, SARS-CoV was primarily transmissible only after symptoms appeared, which made it easier to identify and isolate infected individuals before they spread the virus widely. MERS-CoV, while highly lethal, has a relatively low transmission rate in community settings, with most infections occurring through close contact, such as in healthcare facilities or from infected animals. The basic reproduction number, or R0, reflects these differences in transmission.

SARS-CoV-2 has an R0 estimated at around 2–3 in the early stages of the pandemic, meaning each infected person could potentially infect 2-3 others in the absence of control measures. SARS-CoV had a similar R0 range but was more contained due to the quick onset of symptoms and stricter public health measures. MERS-CoV has an R0 of less than 1 in most circumstances, indicating that it does not sustain widespread person-to-person transmission, although outbreaks have occurred in healthcare settings (22).

Pathogenicity and Clinical Outcomes: The clinical outcomes and mortality rates associated with SARS-CoV, MERS-CoV, and SARS-CoV-2 also show significant differences, likely influenced by variations in viral structure and immune evasion strategies. SARS-CoV-2 has a case fatality rate estimated to be much lower than that of MERS-CoV and slightly lower than SARS-CoV. SARSCoV's fatality rate was approximately 10%, while MERS-CoV has a much higher fatality rate, estimated at 35%. SARS-CoV-2's mortality rate has varied by region and patient demographics but has generally ranged from 1-3%. The differences in fatality rates may be attributed to each virus's interaction with the immune system and the degree to which they provoke inflammation. SARS-CoV-2 often leads to a range of symptoms from mild respiratory issues to severe cases marked by acute respiratory distress syndrome (ARDS) and systemic inflammation. This variability in disease severity could be partially due to SARS-CoV-2's unique evasion mechanisms, which may initially suppress immune responses, allowing the virus to spread before triggering an inflammatory reaction. In contrast, SARS-CoV tends to cause a more rapid immune response, resulting in acute symptoms, while MERS-CoV frequently leads to severe respiratory illness and a stronger inflammatory response, which may contribute to its higher fatality rate (23).

Immune Evasion and Host Response: SARS-CoV-2 has evolved several strategies to evade the host immune response, some of which are shared with SARS-CoV and MERS-CoV. One of the key mechanisms is the suppression of interferon responses, which are critical for early viral detection and clearance. NSP1, an early-expressed non-structural protein, is used by SARS-CoV2 to degrade host mRNA, reducing the host's ability to produce antiviral proteins and initiate an immune response (24). While SARS-CoV and MERS-CoV also interfere with interferon signaling, SARS-CoV-2's mechanisms appear to be more effective in dampening initial immune detection, which may contribute to its greater spread. Another immune evasion tactic involves the spike (S) protein. SARS-CoV-2's spike protein mutations, particularly in variants of concern, have enhanced its ability to bind ACE2 more tightly and evade neutralizing antibodies, a trait observed less frequently in SARS-CoV and MERS-CoV. MERS-CoV, while capable of immune evasion, relies on different mechanisms due to its use of the DPP4 receptor (25).

Mechanisms of SARS-CoV-2 Transmission: The transmission of SARS-CoV-2, the virus that causes COVID-19, occurs through various pathways, each contributing to the virus's ability to spread among populations. Understanding these transmission mechanisms is essential for formulating effective public health strategies aimed at controlling the pandemic. The primary routes of transmission include respiratory droplets, aerosols, direct contact, and fomite transmission. Below is a detailed exploration of each mechanism.

Respiratory Droplets: Respiratory droplets are relatively large particles that are expelled from the respiratory tract when an infected person coughs, sneezes, talks, or even breathes. These droplets typically measure more than 5 micrometres in diameter, making them heavy enough to fall to the ground within a short distance, generally less than 6 feet (approximately 2 meters). This characteristic forms the basis for many of the social distancing guidelines recommended by health authorities. When an infected person expels respiratory droplets, they can directly enter the mouth, nose, or eyes of another individual nearby, leading to infection. The transmission risk increases in enclosed spaces where individuals congregate, as the concentration of droplets in the air can be higher. Factors such as the size of the droplets, the force of the expulsion, and the environmental conditions (such as air currents) all influence how far these droplets can travel (26).

To mitigate the risk of respiratory droplet transmission, several public health measures are recommended such as Mask-Wearing, Masks act as a barrier to block droplets from escaping into the environment and protect the wearer from inhaling droplets from others. Different types of masks provide varying levels of protection, with N95 respirators offering the highest filtration efficiency. Maintaining a distance of at least 6 feet from others reduces the likelihood of droplet transmission. This is especially important in crowded settings. Improving indoor air ventilation helps disperse respiratory droplets more effectively, reducing the concentration of viral particles in the air (27).

Aerosol Transmission: Aerosol transmission involves the spread of smaller particles, known as aerosols, that can remain suspended in the air for extended periods and travel greater distances than respiratory droplets. Aerosols are typically defined as particles that are less than 5 micrometres in diameter. Their small size allows them to be inhaled deeply into the lungs, where they can lead to infection. Aerosols can be generated by similar activities as those that produce respiratory droplets, such as talking, singing, coughing, or sneezing. However, because they can remain airborne for longer periods, aerosol transmission poses a greater risk, particularly in indoor environments with poor ventilation (28). The potential for aerosol transmission means that even if an infected person has left an area, the risk of exposure may persist for those who enter the space afterward. Increasing airflow in indoor spaces can help dilute airborne particles. This can be achieved through natural ventilation (opening windows and doors) or mechanical ventilation systems equipped with HEPA filters that capture smaller particles. Utilizing air purifiers with high-efficiency particulate air (HEPA) filters can help remove airborne viruses and improve air quality. High-quality masks, such as N95 or surgical masks, can significantly reduce the inhalation of aerosols and provide better protection against airborne transmission (29).

Contact Transmission: Contact transmission refers to the transfer of SARS-CoV-2 through physical interactions with infected individuals or contaminated surfaces. This type of transmission can occur in two main forms, 1) Direct Contact: This involves physical interaction with an infected person, such as hugging, shaking hands, or engaging in close conversation. If the infected individual has respiratory secretions containing the virus on their skin, the uninfected person may become infected through this contact. 2) Indirect Contact: This occurs when an individual touches surfaces or objects (fomites) contaminated with the virus. Common surfaces that may harbor the virus include doorknobs, light switches, handrails, and shared equipment. Once the virus is on an uninfected person's hands, touching their face particularly the mouth, nose, or eyes can facilitate infection. To minimize contact transmission, the following practices such as, regular hand washing with soap and water for at least 20 seconds, or using alcohol-based hand sanitizers, can effectively kill the virus on the hands. Frequent cleaning and disinfecting of commonly touched surfaces can reduce the presence of the virus and the risk of indirect transmission. Reducing physical interactions, especially in crowded or enclosed spaces, can limit the opportunity for direct contact transmission (30)

Fomite Transmission: Fomite transmission is a specific type of indirect contact transmission involving the spread of SARS-CoV-2 via contaminated surfaces or objects. Fomites can include everyday items such as smartphones, shopping carts, utensils, and clothing. Although fomite transmission is not the primary route of transmission, it can still contribute to the overall spread of the virus, particularly in settings where people frequently touch the same surfaces. SARS-CoV-2 can survive on various materials for different lengths of time. Studies indicate that the virus can persist longer on hard, non-porous surfaces such as plastic and stainless steel (up to several days) compared to porous materials like cardboard or fabric, where it tends to degrade more

quickly. To reduce the risk of fomite transmission, the following strategies such as, implementing routine cleaning and disinfection protocols for high-touch surfaces in public spaces and at home can help minimize the presence of the virus. Limiting the sharing of personal items and utensils can help reduce the risk of fomite transmission. Whenever possible, individuals should use their own belongings. Practicing good hand hygiene after touching shared surfaces can prevent the transfer of the virus to the face (31).

Viral Entry Mechanisms: Role of ACE2 and TMPRSS2 receptors in host cell entry: The entry of SARS-CoV-2 into host cells is a critical step in the viral replication cycle, enabling the virus to hijack the host's cellular machinery to produce new virions. This process is facilitated by specific interactions between viral proteins and host cell receptors, primarily the angiotensin-converting enzyme 2 (ACE2) and the transmembrane protease, serine 2 (TMPRSS2). A comprehensive understanding of these mechanisms is essential for developing effective therapeutic strategies and preventive measures against COVID-19.

The ACE2 Receptor: ACE2 is a type I membrane protein that plays a vital role in the renin/angiotensin system, which is crucial for regulating blood pressure, fluid balance, and inflammation. It is expressed in various tissues, including the lungs, heart, kidneys, and intestines. In the context of SARS-CoV-2 infection, ACE2 serves as the primary receptor that the virus targets for cell entry.

Mechanism of Viral Entry via ACE2: The spike (S) protein of SARS-CoV-2 is a key determinant of viral entry, consisting of two subunits: S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which directly interacts with the ACE2 receptor on host cells. This interaction is a crucial first step in the viral entry process. When the spike protein binds to ACE2, it triggers a conformational change in the spike structure. This change is essential for the subsequent fusion of the viral envelope with the host cell membrane. The S2 subunit facilitates this fusion process by bringing the viral and host membranes into close proximity, allowing for the release of the viral RNA into the cytoplasm of the host cell. The interaction between the spike protein and ACE2 is characterized by its high affinity, which is influenced by specific amino acid residues in both proteins. Research has shown that certain variants of SARS-CoV-2 have mutations in the spike protein that enhance its binding affinity to ACE2, potentially increasing the virus's transmissibility. Understanding these interactions at a molecular level is crucial for assessing how viral variants may affect public health measures and vaccine efficacy (32).

The Role of TMPRSS2: TMPRSS2 is a type II transmembrane serine protease that plays a critical role in the activation of various viral proteins. It is widely expressed in human tissues, including the respiratory tract, where it facilitates the entry of viruses such as SARS-CoV-2.

Mechanism of Action in Viral Entry: Following the binding of the spike protein to ACE2, TMPRSS2 cleaves the spike protein at specific sites. This cleavage is crucial for activating the spike protein and enabling the fusion process. By processing the spike protein, TMPRSS2 allows the S2 subunit to mediate the fusion of the viral envelope with the host cell membrane effectively. The presence of both ACE2 and TMPRSS2 in the same cell is essential for optimal viral entry. Cells that express both receptors can facilitate efficient entry of SARS-CoV-2, whereas cells lacking one or both may show resistance to infection. This dual requirement highlights the importance of TMPRSS2 in the overall viral entry mechanism and suggests that inhibiting this protease could be a strategic approach for therapeutic interventions (33).

Implications for Therapeutics: Understanding the role of ACE2 and TMPRSS2 in the entry of SARS-CoV-2 has significant implications for developing effective therapeutic strategies. Potential approaches include, The identification and development of TMPRSS2 inhibitors could reduce the infectivity of SARS-CoV-2. By blocking the activity of this protease, these inhibitors would prevent the cleavage and activation of the spike protein, thereby hindering the virus's ability to enter host cells. Several drug candidates are currently under investigation for their ability to inhibit TMPRSS2. Monoclonal antibodies targeting the spike protein can effectively neutralize SARSCoV-2 by blocking its interaction with ACE2. These antibodies are designed to bind specifically to the spike protein, preventing the virus from entering host cells and thereby providing a targeted therapeutic approach for infected patients. Vaccines that elicit robust immune responses against the spike protein can prevent SARS-CoV-2 from binding to ACE2. Current vaccines are designed to provoke an immune response that targets the spike protein, reducing

the likelihood of infection. The development of vaccines based on the spike protein's structure has proven to be a pivotal strategy in controlling the pandemic (34).

Factors influencing transmission: The transmission dynamics of SARS-CoV-2, the virus responsible for COVID-19, are influenced by a variety of factors. Understanding these factors is crucial for developing effective public health strategies and interventions aimed at controlling the spread of the virus. Key determinants of transmission include viral load, host susceptibility, and environmental conditions. Each of these elements plays a significant role in shaping the overall transmission landscape of the virus.

Viral Load: Viral load refers to the amount of viral RNA present in a given volume of bodily fluids, such as respiratory secretions. In the context of SARS-CoV-2, higher viral loads are often associated with increased infectiousness, meaning that individuals with a high viral load are more likely to transmit the virus to others. Individuals infected with SARS-CoV-2 can exhibit varying levels of viral load throughout the course of their infection. Studies have shown that viral load is typically highest in the early stages of infection, particularly just before or around the onset of symptoms. During this time, individuals are more likely to expel large quantities of virus through respiratory droplets and aerosols when they cough, sneeze, talk, or breathe. The relationship between viral load and transmissibility is complex. Higher viral loads can lead to more significant shedding of the virus, increasing the likelihood of exposure for those in close contact. Furthermore, asymptomatic individuals can also have high viral loads, which can contribute to unnoticed transmission within communities. This underscores the importance of testing and monitoring individuals, even those who do not exhibit symptoms, to identify and isolate those with high viral loads and reduce further transmission (35).

Host Susceptibility: Host susceptibility refers to the likelihood of an individual becoming infected after exposure to SARS-CoV-2. Several factors can influence susceptibility, including genetic variations among individuals that can affect the immune response to the virus. Some people may possess genetic traits that enhance their immune response or ability to restrict viral replication, thereby reducing their susceptibility to infection. Age is a significant factor influencing susceptibility. Older adults are generally at higher risk for severe disease and complications from COVID-19, which is believed to be related to a decline in immune function with age. Conversely, younger individuals tend to have stronger immune responses, which can make them less susceptible to infection. Pre-existing health conditions, such as obesity, diabetes, cardiovascular diseases, and respiratory conditions, can increase an individual's susceptibility to SARS-CoV-2 infection. These comorbidities can compromise the immune system or create an environment in which the virus can thrive. Individuals with weakened immune systems, whether due to medical conditions or treatments (such as chemotherapy), are more susceptible to infection and may experience more severe illness if infected. Host susceptibility plays a critical role in determining the spread of the virus within a population. In environments where a high proportion of individuals are susceptible (such as unvaccinated populations), transmission rates can escalate rapidly. Conversely, high vaccination rates and the presence of immunity whether through previous infection or vaccination can significantly reduce overall susceptibility in the population, leading to decreased transmission (36).

Environmental Conditions: The environment in which individuals interact can significantly influence the transmission of SARS-CoV-2. Key environmental factors include, Poorly ventilated indoor spaces can facilitate the accumulation of viral particles in the air, increasing the risk of aerosol transmission. Good ventilation systems that enhance airflow and reduce the concentration of airborne viruses can lower the risk of transmission. Environmental conditions such as temperature and humidity can affect the stability of the virus in the air and on surfaces. Studies have suggested that higher temperatures and humidity levels may reduce the viability of the virus, while low temperatures and dry conditions can enhance its stability and survival outside the host. Fomite transmission, or the transfer of the virus from contaminated surfaces, can occur in various settings, especially in high-touch areas. The persistence of SARS-CoV-2 on surfaces can depend on the material (e.g., plastic, metal, or fabric) and environmental conditions. Regular cleaning and disinfection of surfaces can mitigate this risk (37).

In addition to physical environmental conditions, social behavior also influences transmission. Factors such as community adherence to public health guidelines (e.g., mask-wearing, social distancing, and vaccination) can significantly impact the rate of transmission. Communities that collectively implement preventive

measures tend to experience lower transmission rates. By understanding these factors, public health officials can devise targeted strategies to control transmission, reduce infection rates, and protect vulnerable populations. Continued research into these dynamics will be essential for adapting responses to the evolving nature of the pandemic and ensuring effective measures are in place to mitigate future outbreaks.

Pathogenesis of SARS-CoV-2: Viral Replication Cycle: The pathogenesis of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is intricately tied to its ability to replicate efficiently within host cells. This replication cycle consists of four major phases: entry, replication, transcription, and release. Each of these stages is critical for the virus's propagation and contributes to the overall disease process.

Entry Phase (Initial Contact and Receptor Binding): The viral replication cycle begins when SARS-CoV-2 encounters a susceptible host cell, often through inhalation of respiratory droplets containing the virus. The spike (S) protein on the surface of the virus is essential for this initial interaction. The spike protein binds specifically to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface. ACE2 is expressed in various tissues, but it is particularly abundant in the epithelial cells of the lungs, intestines, kidneys, and blood vessels, making these tissues prime targets for infection. This binding triggers conformational changes in the spike protein, enabling it to facilitate membrane fusion between the viral envelope and the host cell membrane. This process may be further enhanced by the action of host cell proteases, specifically transmembrane protease, serine 2 (TMPRSS2), which cleaves the spike protein, making it more efficient at promoting fusion. Once the membranes are fused, the viral envelope merges with the host cell membrane, allowing the viral RNA genome to be released into the cytoplasm (38).

Replication Phase: Once inside the host cell, the viral RNA genome undergoes Uncoating, which involves the disassembly of the viral particle and exposure of the RNA to the cytoplasmic environment. SARS-CoV-2 possesses a positive-sense single-stranded RNA genome, which means it can directly serve as messenger RNA (mRNA) for translation by the host's ribosomes. The first step in the replication process involves the translation of the viral RNA into two large polyproteins, pp1a and pp1ab. These polyproteins are subsequently cleaved by viral proteases into several functional non-structural proteins (nsps). These nsps are crucial for the virus's replication and include, RNA-dependent RNA polymerase (RdRp) which is responsible for synthesizing new viral RNA genomes. These nsps cleave polyproteins into functional units, facilitating the assembly of the replication complex. The newly synthesized non-structural proteins assemble to form a replication-transcription complex that facilitates the synthesis of new viral genomes. This involves the creation of a complementary negative-sense RNA strand, which serves as a template for producing additional positive-sense RNA genomes and sub genomic mRNAs. This replication process is highly efficient, allowing the virus to rapidly increase its numbers within the host cell (39).

Transcription Phase: During the transcription phase, the viral replication complex synthesizes sub genomic mRNAs from the negative-sense RNA templates. These sub genomic mRNAs encode for several structural and accessory proteins required for the assembly of new virions. The primary proteins synthesized during this phase include Spike (S) Protein which is vital for the virus's ability to attach to host cells and facilitate entry. Nucleocapsid (N) Protein which binds to the viral RNA, forming the nucleocapsid and protecting the viral genome. Membrane (M) and Envelope (E) Proteins which are important for the structural integrity of the virions and the assembly process. The transcription of these viral proteins is tightly regulated, ensuring that the necessary quantities of each protein are produced for efficient assembly and release of new virions (40).

Release Phase: Following the synthesis of viral proteins and RNA, the assembly of new virions takes place. Structural proteins, including M, E, and S proteins, are directed to the endoplasmic reticulum (ER) and Golgi apparatus, where they are incorporated into the membranes of these organelles. The nucleocapsid, which consists of the RNA genome and N protein, is packaged with the envelope proteins in a process that ensures each new virion contains the necessary components for infection. Once the new virions are assembled, they exit the host cell through a process known as budding. During budding, the new virions acquire their lipid envelope from the host cell membrane. This process is critical, as it allows the virions to exit the cell without causing immediate lysis, which would otherwise destroy the host cell and prevent further viral propagation. After budding, the new virions are transported to the cell

surface in vesicles, where they fuse with the plasma membrane. This exocytosis process releases mature virions into the extracellular space, allowing them to infect neighbouring cells and perpetuate the infection (41).

The viral replication cycle of SARS-CoV-2 is a multi-faceted process encompassing entry, replication, transcription, and release phases. Each of these stages is essential for the virus's ability to propagate and establish infection within the host. Understanding the detailed mechanisms underlying these phases not only enhances our knowledge of SARS-CoV-2 pathogenesis but also identifies potential therapeutic targets. For instance, antiviral agents can be developed to inhibit specific steps of the replication cycle, such as entry inhibitors that block the interaction between the spike protein and ACE2 or polymerase inhibitors that disrupt RNA synthesis. In addition, insights into the viral life cycle can inform vaccine development strategies that aim to elicit strong immune responses against critical viral components. By comprehensively understanding the pathogenesis of SARS-CoV-2, researchers and public health officials can devise more effective measures to control COVID-19, reducing its impact on global health and aiding in the management of future viral outbreaks (42).

Host-Pathogen Interactions (How SARS-CoV-2 Affects Host Cells): The interaction between SARS-CoV-2, the virus responsible for COVID-19, and host cells is a critical area of study for understanding the disease's pathogenesis. These interactions lead to significant alterations in cellular functions, immune responses, and ultimately result in tissue damage. The complex interplay between the virus and host cells can be delineated into several key processes: viral entry and its effects on cellular signaling, the induction of inflammation, cellular damage mechanisms, and immune evasion strategies (43). Each of these processes is crucial for the virus's ability to replicate and cause disease.

Viral Entry and Its Impact on Cellular Processes: SARS-CoV-2 primarily utilizes the spike (S) protein to engage with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. This interaction is fundamental for viral entry and occurs predominantly in cells of the respiratory tract, but ACE2 is also expressed in other tissues, such as the heart, kidneys, and gastrointestinal tract. The binding of the spike protein to ACE2 not only facilitates entry but also initiates a cascade of intracellular signaling events. ACE2 serves a dual function; it regulates the renin-angiotensin system, which is involved in blood pressure control and fluid balance. When SARS-CoV-2 binds to ACE2, it disrupts this regulatory mechanism, leading to an accumulation of angiotensin II, a peptide that promotes inflammation, vasoconstriction, and fibrosis. This dysregulation can contribute to the systemic manifestations of COVID-19, including acute respiratory distress syndrome (ARDS) and cardiovascular complications (44).

Upon entry, the virus manipulates various host signaling pathways to favour its replication. The infection triggers an array of intracellular responses, including the activation of PRRs such as Tolllike receptors (TLRs), which are essential for detecting viral components. While this activation aims to mount an immune response, SARS-CoV-2 can subvert these pathways. For instance, the virus can down regulate the expression of type I interferons (IFN-α and IFN-β), key mediators in antiviral defense. This suppression not only hinders the immediate antiviral response but also allows for enhanced viral replication, as the host's antiviral state is compromised (45).

Induction of Inflammation: The host's immune response to SARS-CoV-2 infection is characterized by the release of pro-inflammatory cytokines and chemokines. This response is critical for recruiting immune cells to the site of infection but can become pathological when excessively activated. Cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) are released by infected and neighbouring cells in an effort to control the viral load. However, the dysregulation of this inflammatory response can lead to a cytokine storm, a hyper-inflammatory state that can cause extensive tissue damage, particularly in the lungs. The excessive accumulation of inflammatory mediators leads to increased vascular permeability, resulting in pulmonary edema and ARDS. This condition is marked by the infiltration of immune cells into lung tissue, which can further exacerbate inflammation and disrupt normal pulmonary function. In severe cases of COVID-19, the cytokine storm can trigger a systemic inflammatory response syndrome (SIRS), affecting multiple organ systems. The inflammatory mediators not only harm the lungs but can also lead to dysfunction in other organs, including the heart, liver, and kidneys. The result is a cascade of events that culminates in multi-organ failure,

highlighting the importance of regulating inflammation in managing COVID-19 (46).

Cellular Damage and Apoptosis: The replication of SARS-CoV-2 within host cells can lead to direct cellular injury. The virus's life cycle results in the accumulation of viral components, which can disrupt normal cellular processes and lead to cell death. Infected cells may undergo apoptosis, a programmed cell death mechanism that is triggered in response to stress or damage. The presence of viral RNA and proteins within the cytoplasm can activate apoptotic pathways, including the intrinsic pathway involving mitochondrial dysfunction and the extrinsic pathway triggered by death receptors. This apoptotic process can lead to the death of both infected and nearby uninfected cells, contributing to the overall tissue damage observed in COVID-19. Infected tissues may display necrosis as well, a form of cell death that results from acute injury and is often accompanied by inflammation (47). In addition to direct cytopathic effects, SARS-CoV-2 alters the metabolic state of host cells to favour viral replication. Infected cells often shift their metabolism towards glycolysis and other pathways that support the rapid production of viral components. This metabolic reprogramming can compromise cellular functions and contribute to the overall pathophysiology of COVID-19. For example, the virus can induce endoplasmic reticulum (ER) stress, leading to an unfolded protein response (UPR), which further affects cell viability and function (48).

Immune Evasion Mechanisms: SARS-CoV-2 employs multiple strategies to evade the host immune response. One of the key mechanisms is the down regulation of type I interferon signaling, which is essential for initiating an effective antiviral response. By inhibiting the production and action of type I interferons, SARS-CoV-2 effectively suppresses the activation of immune cells, particularly CD8+ T cells and natural killer (NK) cells, which are crucial for controlling viral infections. The virus also influences the function of various immune cells, including macrophages and dendritic cells. Infected macrophages can become polarized towards a pro-inflammatory phenotype (M1), which can exacerbate tissue damage through the production of additional inflammatory mediators (49). Conversely, the presence of the virus can impair the maturation and function of dendritic cells, limiting their ability to present viral antigens to T cells and diminishing the adaptive immune response. Moreover, the virus can induce lymphopenia, a reduction in lymphocyte counts, particularly affecting CD4+ and CD8+ T cells, which weakens the adaptive immune response. This lymphopenia is associated with worse clinical outcomes in COVID-19 patients, as the body's ability to mount a targeted immune response against the virus is compromised (50).

The interactions between SARS-CoV-2 and host cells are complex and multifaceted, leading to significant alterations in cellular processes, immune responses, and ultimately tissue damage. By understanding these interactions, researchers can identify potential therapeutic targets to mitigate the effects of the virus. Strategies such as antiviral therapies that inhibit viral replication, immune modulators to control excessive inflammation, and vaccines to boost adaptive immunity are crucial in combating COVID-19. In particular, therapies aimed at regulating the inflammatory response may help prevent the severe complications associated with a cytokine storm, while antiviral agents could effectively limit viral replication and spread (51). Continued research into the mechanisms of host-pathogen interactions will provide deeper insights into COVID-19 pathogenesis and inform the development of innovative treatment approaches. By addressing these interactions comprehensively, the medical community can improve clinical outcomes for patients and enhance public health responses to future viral outbreaks.

Systemic Effects of SARS-CoV-2 (Organ Systems Affected): SARS-CoV-2, the virus responsible for COVID-19, is primarily known for its impact on the respiratory system. However, emerging evidence has demonstrated that the virus can affect multiple organ systems throughout the body. This systemic involvement contributes to the diverse clinical manifestations of COVID19, ranging from mild symptoms to severe complications (52). Understanding the systemic effects of SARS-CoV-2 is crucial for managing the disease and developing comprehensive treatment strategies.

Respiratory System: The respiratory system is the primary site of SARS-CoV-2 entry and replication. Infection can lead to a spectrum of respiratory symptoms, from mild cough and sore throat to severe pneumonia and acute respiratory distress syndrome (ARDS). The virus binds to ACE2 receptors present on the epithelial cells of the respiratory tract, leading to cell damage and inflammation. The resultant immune response can cause alveolar damage, edema, and impaired gas exchange. Patients often present with

symptoms such as dyspnea (shortness of breath), cough, and chest pain. In severe cases, the inflammatory response can progress to ARDS, characterized by diffuse alveolar damage, hypoxemia, and respiratory failure, requiring mechanical ventilation. Post-acute sequelae of SARS-CoV-2 infection, often referred to as "long COVID," may involve persistent respiratory symptoms such as chronic cough and reduced lung function (53).

Cardiovascular System: SARS-CoV-2 infection has profound effects on the cardiovascular system, increasing the risk of thromboembolic events and myocardial injury. The virus can directly infect cardiac myocytes, leading to inflammation of the myocardium (myocarditis) and potentially resulting in acute heart failure. Elevated troponin levels in COVID-19 patients indicate myocardial injury, even in those without prior heart disease. COVID-19 is associated with a higher incidence of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). The inflammatory state induced by the virus contributes to a hypercoagulable state, increasing the risk of clot formation. Patients may experience arrhythmias due to electrolyte imbalances, inflammation, and direct cardiac injury. These can lead to complications such as sudden cardiac arrest (54).

Nervous System: The central and peripheral nervous systems can also be impacted by SARSCoV-2, leading to a variety of neurological symptoms. Although the virus primarily targets the respiratory system, it has been detected in the cerebrospinal fluid (CSF) and brain tissue, suggesting potential neurotropism. The mechanisms by which the virus enters the central nervous system (CNS) may include hematogenous spread or via the olfactory pathway. Common neurological symptoms reported in COVID-19 patients include headaches, dizziness, loss of taste and smell (anosmia), and cognitive dysfunction. Severe cases may lead to more serious complications, such as encephalitis and Guillain-Barre syndrome, an autoimmune condition that affects peripheral nerves. Survivors of COVID-19 may experience prolonged cognitive and neurological impairments, sometimes referred to as "brain fog," which includes difficulty concentrating, memory issues, and emotional disturbances (55).

Gastrointestinal System: Gastrointestinal symptoms are prevalent in COVID-19 patients and can occur even in the absence of respiratory symptoms. Symptoms may include diarrhoea, nausea, vomiting, and abdominal pain. These symptoms can arise early in the disease and may be a result of direct viral infection of the gastrointestinal epithelium. The presence of ACE2 receptors in the gastrointestinal tract provides a potential route for SARS-CoV-2 entry. Viral replication in enterocytes can disrupt gut function and contribute to gastrointestinal symptoms. COVID-19 may also alter the gut microbiome, leading to dysbiosis, which can have implications for overall health and recovery. Changes in gut microbiota have been associated with increased inflammation and immune dysregulation (56).

Renal System: The kidneys can also be affected by SARS-CoV-2, leading to acute kidney injury (AKI) in some patients. The virus may directly infect renal tubular cells, leading to tubular damage and dysfunction. AKI is often associated with severe cases of COVID-19 and can result from various factors, including hypoxia, sepsis, and nephrotoxic medications. Elevated serum creatinine and proteinuria are common indicators of kidney injury in COVID-19 patients. In severe cases, renal replacement therapy may be necessary (57).

Beyond the aforementioned organ systems, SARS-CoV-2 may impact other areas of health. COVID-19 can lead to lymphopenia (a decrease in lymphocyte count), thrombocytopenia (a decrease in platelets), and coagulopathy, contributing to increased risk of clotting disorders. There is evidence suggesting potential impacts on glucose metabolism and thyroid function, possibly leading to stress-induced hyperglycemia or thyroid dysfunction.

Skin rashes and other dermatological symptoms have been reported in COVID-19 patients, indicating systemic involvement (58). The systemic effects of SARS-CoV-2 extend well beyond the respiratory system, affecting multiple organ systems and leading to a range of clinical manifestations. The interplay of direct viral effects, immune-mediated damage, and systemic inflammation underlies the complexity of COVID-19 pathology.

Understanding these systemic effects is crucial for developing comprehensive treatment strategies and managing the long-term consequences of the disease. As research continues to evolve, it will be vital to monitor the full spectrum of SARS-CoV-2's impact on health and to address the diverse needs of patients recovering from COVID-19. This holistic approach can aid in mitigating the pandemic's effects and improving patient outcomes (59).

Immune Response to SARS-CoV-2: Innate Immune Response

The immune system's response to SARS-CoV-2, the virus responsible for COVID-19, is intricate and involves two primary branches: the innate immune system and the adaptive immune system. This discussion will focus on the innate immune response, which serves as the body's first line of defense against the viral infection. It encompasses the initial immune reactions, the crucial role of interferon production, and the release of inflammatory cytokines (60).

Initial Immune Reactions: The response to SARS-CoV-2 infection begins the moment the virus enters the host. The innate immune system is equipped to recognize and respond to viral infections almost immediately, utilizing specialized receptors to identify viral components.

Pattern Recognition Receptors (PRRs): These receptors are vital for the detection of pathogens. Among them, Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) play critical roles in recognizing viral nucleic acids and proteins. These receptors are present on various immune cells, including macrophages, dendritic cells, and epithelial cells. Once PRRs detect SARS-CoV-2, they activate signaling pathways that result in the production of various immune mediators. This process triggers a cascade of events that mobilizes immune cells to the site of infection, preparing the body to combat the virus. Phagocytes, such as macrophages and neutrophils, are recruited to the infected area to engulf and destroy virus particles and infected cells. This phagocytic activity is crucial in controlling the spread of the virus and facilitating tissue repair (61).

Interferon Response: One of the hallmark features of the innate immune response to viral infections is the production of interferons (IFNs), which are key signaling molecules that play a central role in antiviral defense. Type I Interferons, Upon detection of SARS-CoV-2, infected cells rapidly produce type I interferons, particularly interferon-alpha (IFN-α) and interferon-beta (IFN-β). These cytokines are critical for establishing an antiviral state in neighbouring uninfected cells. Type I interferons bind to the interferon-α/β receptor (IFNAR) on surrounding cells, activating intracellular signaling pathways that lead to the expression of a wide array of interferon-stimulated genes (ISGs). These ISGs produce proteins that inhibit viral replication, enhance the immune response, and improve antigen presentation, thereby bolstering the body's ability to fight off the infection. Despite the importance of the interferon response, SARS-CoV-2 has evolved mechanisms to evade this defense. The virus can interfere with interferon signaling pathways, which may help it persist and replicate within the host (62).

Inflammatory Cytokine Release: In conjunction with interferon production, the innate immune response also involves the release of a variety of pro-inflammatory cytokines and chemokines that are essential for orchestrating an effective immune response. Infected cells and activated immune cells produce numerous inflammatory mediators, such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). These cytokines play pivotal roles in promoting inflammation and orchestrating the immune response. The inflammatory cytokines released during infection serve to attract additional immune cells to the site of viral replication. For example, IL-6 is known for its ability to recruit neutrophils and stimulate the differentiation of T cells, thereby enhancing the overall immune response. While inflammation is necessary to combat the virus, excessive or dysregulated inflammation can lead to significant tissue damage. This phenomenon, commonly referred to as a "cytokine storm," may result in severe complications such as acute respiratory distress syndrome (ARDS) and multi-organ failure (63).

Balance between Immune Activation and Regulation: A critical aspect of the innate immune response is the balance between immune activation and regulation. To prevent the potentially damaging effects of an overly robust immune response, regulatory mechanisms are activated. These include the activity of regulatory T cells (Tregs) and the production of anti-inflammatory cytokines, which help modulate the immune response and protect against excessive tissue damage. The effectiveness of the innate immune response plays a pivotal role in determining the outcome of SARS-CoV-2 infection. A well-coordinated and timely response can limit viral replication and disease severity, while an inadequate or overly aggressive response can lead to adverse clinical outcomes (64).

The innate immune response to SARS-CoV-2 is a fundamental component of the host's defense against the virus. Through the recognition of viral components, the

production of interferons, and the release of inflammatory cytokines, the innate immune system works diligently to control viral replication and initiate a comprehensive immune response. However, the ability of SARS-CoV-2 to evade certain innate immune mechanisms, along with the risks associated with excessive inflammation, highlights the complexity of the immune response to this novel virus. A thorough understanding of these processes is essential for the development of effective therapies and vaccines aimed at mitigating the effects of COVID-19. Ongoing research will continue to shed light on the intricate dynamics of the innate immune response and its implications for public health and clinical practice (65).

Adaptive Immune Response to SARS-CoV-2: The adaptive immune response is a crucial component of the immune system that provides a targeted and specific defense against pathogens like SARS-CoV-2. This response is characterized by the activation of T cells and B cells, which work in concert to eliminate the virus and establish long-term immunity. Understanding the mechanisms of T-cell and B-cell responses, antibody production, and memory immunity is essential for appreciating how the body combats SARS-CoV-2 and develops protection against future infections (66).

T-cell Responses: T cells are pivotal players in the adaptive immune response and can be broadly categorized into two main types: CD4+ T helper cells and CD8+ cytotoxic T cells. CD4+ T Cells (T Helper Cells), Upon recognizing viral antigens presented by major histocompatibility complex (MHC) class II molecules on antigen-presenting cells (APCs), CD4+ T cells become activated. They play a critical role in orchestrating the immune response by releasing cytokines that enhance the activity of other immune cells, including B cells and CD8+ T cells. In the context of SARS-CoV-2, T helper cells support the development of a robust antibody response and help activate cytotoxic T cells. CD8+ T Cells (Cytotoxic T Lymphocytes), These cells are responsible for directly targeting and killing virus-infected cells. They recognize viral peptides presented by MHC class I molecules on the surface of infected cells. Once activated, CD8+ T cells proliferate and differentiate into effector cells, which release cytotoxic granules containing perforin and granzymes to induce apoptosis in infected cells, thus limiting viral replication. T cells also produce a variety of cytokines, such as interferon-gamma (IFN-γ), which further enhances the antiviral response by activating macrophages and promoting the recruitment of additional immune cells (67).

B-cell Responses and Antibody Production: B cells are responsible for the production of antibodies, which are critical for neutralizing viruses and preventing their spread within the host. Upon encountering viral antigens, B cells can become activated either directly through antigen binding or indirectly with the help of CD4+ T cells. Activated B cells undergo clonal expansion and differentiation into plasma cells, which are specialized for antibody production. Plasma cells produce large quantities of antibodies specific to SARS-CoV-2. These antibodies can neutralize the virus by binding to the spike protein, preventing the virus from entering host cells. The main classes of antibodies produced include immunoglobulin M (IgM), which provides early response, and immunoglobulin G (IgG), which offers long-lasting protection. Neutralizing antibodies play a vital role in controlling the infection by blocking viral entry into host cells. Their presence in the bloodstream can significantly reduce the severity of the disease and contribute to the recovery of infected individuals (68).

Memory Immunity: A key feature of the adaptive immune response is the generation of immunological memory, which allows the immune system to respond more rapidly and effectively upon re-exposure to the same pathogen. Following an infection, some CD4+ and CD8+ T cells differentiate into memory T cells, which persist in the body for years. These memory cells enable a quicker and more robust response to subsequent infections with SARS-CoV-2. Memory T cells can remain in peripheral tissues and the lymphatic system, ready to respond to a reinfection. Similarly, some activated B cells develop into memory B cells, which circulate in the body and can quickly produce antibodies upon re-encountering the virus. This rapid response is crucial for preventing reinfection and contributes to long-term immunity. Studies have shown that memory T and B cells specific to SARS-CoV-2 can persist for several months to years after infection, providing a significant level of protection against reinfection. The durability of this memory response is an important factor in the long-term management of COVID-19 and vaccine effectiveness (69).

The adaptive immune response to SARS-CoV-2, involving both T cells and B cells, is integral to the body's ability to control and eliminate the virus.

Through the activation of T cells, the production of antibodies by B cells, and the establishment of immunological memory, the adaptive immune system equips the host with the tools needed to fight off the virus effectively and to provide protection against future infections. Understanding these mechanisms is crucial for developing effective vaccines and therapeutic strategies that enhance the immune response to SARS-CoV-2 and ultimately help mitigate the impact of COVID-19 on public health. Ongoing research is essential to further elucidate the nuances of the adaptive immune response and its implications for managing this global pandemic (70).

Immune Evasion Strategies of SARS-CoV-2: SARS-CoV-2, the virus responsible for COVID19, exhibits a remarkable ability to evade the host immune response, allowing it to persist and spread effectively. This section explores the mechanisms by which the virus avoids detection and neutralization by the immune system, particularly focusing on the modulation of interferon pathways, the delay of immune responses, and other immune evasion strategies.

Modulation of Interferon Pathways: Interferons (IFNs) are critical components of the innate immune response, serving as key signaling molecules that help coordinate the body's defense against viral infections. SARS-CoV-2 has evolved several strategies to modulate and disrupt interferon signaling, which is crucial for its survival and replication. Upon infecting a host cell, SARS-CoV-2 has evolved mechanisms to inhibit the production of type I interferons (IFNs), crucial antiviral proteins. Ordinarily, the detection of viral elements by pattern recognition receptors (PRRs) would activate IFN-α and IFN-β, but SARS-CoV-2 interferes with this process through specific viral proteins. For instance, nsp1 binds to host messenger RNA, effectively halting its translation and, in turn, dampening the host's IFN response. Another protein, nsp3, targets retinoic acid-inducible gene I (RIG-I), a pivotal PRR for identifying viral RNA, thus obstructing the pathway that leads to IFN production. Additionally, nsp6 disrupts the formation of signaling complexes essential for IFN induction, further reducing the host's antiviral response (71).

Beyond inhibiting IFN production, SARS-CoV-2 impairs IFN signaling pathways to evade immune responses. After IFNs bind to their receptors, they usually trigger a series of events via the JAK-STAT pathway, ultimately leading to the expression of interferon-stimulated genes (ISGs) with antiviral functions. SARS-CoV-2 counters this by producing proteins that block JAK activation, preventing STAT proteins from being phosphorylated and translocating to the nucleus to initiate ISG transcription. Moreover, certain viral proteins can inhibit ISG functions directly, which would normally work to curb viral replication and bolster immune defences. By evading the antiviral effects of ISGs, SARS-CoV-2 enhances its own replication and ability to persist within the host. This suppression of interferon responses at multiple stages aids the virus in evading immune detection and amplifying its infectivity (72).

Delayed Immune Response: The timing of immune activation plays a pivotal role in determining the success of the body's response to viral infections. SARS-CoV-2 has evolved specific strategies to postpone the onset of both innate and adaptive immune responses, allowing it to gain an advantage in early infection stages. One such strategy involves delaying the presentation of viral antigens, which is essential for initiating an effective T-cell response. By slowing the process through which infected cells display viral antigens to T cells, SARS-CoV-2 enables itself to reach higher replication levels before the immune system can effectively counteract it (73). Additionally, the virus can manipulate immune checkpoints to hinder T-cell activation; for instance, it upregulates PD-L1 expression on infected cells, which binds to PD-1 on T cells, leading to T-cell exhaustion and reduced immune efficiency. SARS-CoV-2 further modulates cytokine production, disrupting the signals required to fully activate and regulate immune responses, thus dampening T-cell activity and response speed. The virus also achieves immune evasion by downregulating MHC class I molecules, which play a critical role in presenting antigens to CD8+ T cells. This suppression of MHC molecules on infected cells conceals the virus from cytotoxic T cells, enabling it to persist and spread within the host while facing delayed immune detection (74).

Other Immune Evasion Tactics: In addition to modulating interferon responses and delaying immune activation, SARS-CoV-2 employs various other strategies to evade the immune system. The virus exhibits genetic variability, leading to the emergence of new variants. Some of these variants have mutations in the spike protein, which can alter the virus's antigenic profile. This variability can allow the virus to escape

recognition by neutralizing antibodies developed during previous infections or vaccinations (75). Although still under investigation, some evidence suggests that SARS-CoV-2 may have the potential to establish a latent infection in certain cell types. This ability to remain dormant allows the virus to evade the immune system while being able to reactivate under favourable conditions, complicating eradication efforts. SARS-CoV-2 can modulate the function of various immune cells to favour its persistence. For example, it can alter the functions of dendritic cells, which play a critical role in antigen presentation and T-cell activation, leading to ineffective immune responses. The virus can induce a dysregulated inflammatory response, leading to what is commonly referred to as a "cytokine storm." This hyperinflammatory response can cause significant tissue damage, further complicating the immune response and allowing the virus to thrive in a chaotic immunological environment (76).

Implications for Immunity and Long-term Protection: Duration of Immunity: The global impact of the COVID-19 pandemic caused by SARS-CoV-2 has generated significant interest in understanding the nature and duration of immunity following infection or vaccination. This knowledge is essential for guiding public health decisions, informing vaccination strategies, and managing the ongoing response to the pandemic. This section examines the dynamics of immune memory generated by SARS-CoV-2 and highlights the implications of reinfection cases (77).

Immune Memory Following SARS-CoV-2 Infection: When SARS-CoV-2 infects the body, the immune system's adaptive branch initiates a targeted response, particularly through B cells and T cells. B cells play a fundamental role by differentiating into plasma cells, which produce antibodies that specifically recognize and neutralize the virus. Among these, immunoglobulin G (IgG) is particularly effective in binding to SARS-CoV-2 and preventing its entry into host cells.

Alongside plasma cells, memory B cells are formed, which retain information about the virus, allowing for a rapid and effective antibody response upon future exposures (78). The adaptive immune response also involves the activation of T cells. CD4+ helper T cells support B cell activation and stimulate antibody production, while CD8+ cytotoxic T cells directly target and destroy infected cells. Memory T cells generated during this initial immune response provide a foundation for quick mobilization if reinfection occurs. Notably, studies suggest that both CD4+ and CD8+ T cells remain detectable in the body for several months post-recovery, contributing to prolonged immunity. Immune memory following natural infection can last from 6 to 12 months or longer, although the duration and robustness of this memory may vary depending on factors such as age, health status, and the severity of the original infection (79).

Reinfection Cases: Despite the development of immune memory, instances of reinfection with SARS-CoV-2 have been reported, raising critical questions regarding the longevity of immunity and the possibility of long-term protection. Reinfections can result from various factors such as the virus can undergo mutations that alter its surface proteins, particularly in key areas recognized by the immune system. Variants such as Delta and Omicron have demonstrated the ability to partially evade the immune response generated by previous infections or vaccinations, leading to an increased likelihood of reinfection (80). Over time, antibody levels against SARS-CoV-2 may diminish, which can reduce the body's ability to neutralize the virus upon re-exposure. This decline can heighten susceptibility to reinfection, especially when encountering a variant that has diverged significantly from the strain responsible for the initial infection. Reports of reinfection reveal a spectrum of clinical outcomes. Some reinfections present with mild or asymptomatic cases, while others can lead to severe illness. The severity of reinfection may depend on multiple factors, including the individual's immune status, the specific variant involved, and the time elapsed since the original infection or vaccination. The possibility of reinfections underscores the importance of continuous monitoring of viral variants and the effectiveness of vaccines over time. Public health strategies may need to adapt in response to changes in immunity, including recommendations for booster vaccinations to enhance and prolong immune protection (81).

Vaccine-Induced Immunity: Vaccination against SARS-CoV-2 has emerged as a critical tool in controlling the spread of COVID-19. Vaccines are designed to elicit a robust immune response similar to that generated by natural infection. Initial data suggested that the immune protection afforded by vaccines could be effective for several months against both infection and severe disease. However, as with natural immunity, levels of antibodies may decrease over time, leading to

the recommendation for booster shots to maintain adequate protection against the virus. Booster doses have been shown to significantly enhance antibody levels and restore protection, particularly against emerging variants of concern. Ongoing research is focused on determining the optimal timing and formulation for booster vaccinations to maximize the duration and efficacy of immune responses (82).

Variants and Immune Escape: Impact of SARS-CoV-2 Variants on Immunity

The emergence of variants of SARS-CoV-2 has become a critical focus in understanding the pandemic, particularly concerning their effects on transmission dynamics and immune escape. As the virus evolves, specific mutations can enhance its ability to spread and evade the host immune response, which has significant implications for public health, vaccine efficacy, and therapeutic strategies. This section delves into how these variants influence immunity and the underlying mechanisms that facilitate immune evasion (83).

1. Understanding SARS-CoV-2 Variants

SARS-CoV-2 variants arise through mutations that occur during viral replication. These mutations can happen in various parts of the virus, including genes encoding surface proteins that are crucial for the virus's ability to infect host cells. Key variants have been categorized based on their potential impact on transmissibility and virulence. Several variants have drawn particular attention due to their significant implications for public health.

The Alpha variant, also known as B.1.1.7, was initially identified in the United Kingdom and became notable for its increased transmissibility and a potential rise in disease severity. Following this, the Beta variant (B.1.351) emerged in South Africa, carrying mutations that contributed to a heightened ability to evade immune responses, thereby raising questions about the efficacy of existing vaccines. Around the same time, the Gamma variant (P.1) was reported in Brazil, sharing similar mutations linked to immune escape. The Delta variant (B.1.617.2), first detected in India, quickly spread across multiple countries due to its high rate of transmission and a partial ability to evade immunity. More recently, the Omicron variant (B.1.1.529) surfaced in South Africa, distinguished by a large number of mutations, especially within the spike protein. These mutations led to substantial concerns about its potential for immune escape and the implications this might have for vaccine effectiveness (84).

2. Impact on Transmission

The mutations observed in various SARS-CoV-2 variants have significant implications for viral transmission. These alterations, particularly in the spike protein, often enhance the virus's capacity to attach to host cell receptors, notably the ACE2 receptor, thereby improving its entry into human cells. This mechanism has been particularly evident in variants such as Delta and Omicron, which have exhibited significantly higher transmission rates than earlier strains. Research indicates that this increased transmissibility may be attributed to shifts in viral shedding patterns and a higher viral load in individuals infected with these variants (85). As a result, even vaccinated populations are at a greater risk of infection and subsequent spread. Moreover, the rapid proliferation of certain variants has led to the occurrence of superspreader events, where a single infected individual can give rise to numerous cases in a short time. This situation underscores the critical importance of continuous surveillance and the need for swift public health responses to effectively manage emerging variants and their potential impact on community health.

3. Immune Evasion Mechanisms

One of the most concerning features of some SARS-CoV-2 variants is their ability to escape immune detection and neutralization. This immune evasion can occur through several mechanisms, Many key mutations in variants are located in the spike protein, the primary target for neutralizing antibodies generated through natural infection and vaccination. These mutations can alter epitopes recognized by the immune system, reducing the effectiveness of neutralizing antibodies. For example, the E484K mutation, found in variants like Beta and Gamma, has been associated with a reduced neutralizing response. The presence of specific mutations has raised concerns about the effectiveness of vaccines. While most vaccines still provide strong protection against severe disease and hospitalization, some studies indicate diminished efficacy against infection with variants such as Delta and Omicron. This has led to increased recommendations for booster doses to enhance immunity and broaden protection against

emerging variants. Variants can also affect T-cell recognition. Although some mutations may primarily impact antibody neutralization, they can also influence the presentation of viral peptides to T cells. Variants that evade T-cell recognition can compromise the cellular immune response, potentially leading to more severe disease upon reinfection (86).

4. Implications for Public Health and Vaccine Strategy

The impact of SARS-CoV-2 variants on immunity underscores the need for adaptive public health strategies. Continuous genomic surveillance is essential to monitor emerging variants and their mutations to inform vaccine updates and therapeutic approaches. Vaccine manufacturers are exploring the development of modified vaccines that can specifically target prevalent variants. This may include the formulation of multivalent vaccines that can elicit a broader immune response against multiple strains of the virus. Enhanced surveillance and rapid response strategies are critical in containing outbreaks associated with variants. This may involve reinforcing mask mandates, optimizing testing and contact tracing, and promoting vaccination and booster campaigns, especially in areas with rising variant prevalence (87).

Herd Immunity and Vaccination (The Role of Vaccination in Establishing Herd Immunity and Controlling Transmission): Herd immunity is a crucial public health goal in managing infectious diseases, including COVID-19, caused by the SARS-CoV-2 virus. This concept involves protecting the entire population from an infectious disease when a substantial portion of the community becomes immune, either through vaccination or prior infection. Vaccination is particularly pivotal in achieving herd immunity against COVID-19, as it plays a vital role in controlling the virus's transmission and mitigating its impact on public health (88).

Herd immunity occurs when a significant percentage of a population is immune to a specific disease, making the spread of the pathogen less likely. This situation protects those who are not immune, including individuals who cannot receive vaccinations due to health conditions, young children, or those with weakened immune systems. The percentage of the population that needs to be immune to achieve herd immunity varies depending on the infectious disease's transmissibility. For SARS-CoV-2, research suggests that approximately 70% to 90% of individuals may need to be immune to significantly curb the spread of the virus. Factors such as the presence of new variants can influence this threshold, highlighting the dynamic nature of achieving herd immunity in the context of COVID-19 (89). Vaccination is a primary method to establish herd immunity, as it effectively prepares the immune system to recognize and combat the virus without causing disease. Vaccines designed for COVID-19 have been developed using various technologies, including mRNA and viral vectors. COVID-19 vaccines stimulate an immune response by introducing harmless components of the virus, such as the spike protein, which prompts the body to produce specific antibodies. This response not only helps individuals fight off the virus if exposed but also contributes to a broader community immunity when a large portion of the population is vaccinated. Widespread vaccination reduces the likelihood of virus transmission within communities. When enough individuals are vaccinated, the overall pool of susceptible hosts decreases, thereby limiting opportunities for the virus to spread. This is particularly important in interrupting transmission chains and protecting vulnerable populations (90).

Despite the clear benefits of vaccination in establishing herd immunity, several challenges must be addressed to reach this goal effectively. Misinformation, cultural beliefs, and distrust in healthcare systems contribute to vaccine hesitancy. Individuals may delay or refuse vaccination, which can undermine efforts to achieve herd immunity. Public health campaigns aimed at educating communities about vaccine safety and efficacy are essential to counteract this hesitancy and increase vaccination rates. The emergence of new SARS-CoV-2 variants poses additional challenges to achieving herd immunity. Variants may exhibit mutations that enhance transmissibility or confer some degree of immune evasion, complicating the landscape of vaccination efforts. These variants can potentially diminish the effectiveness of existing vaccines, necessitating ongoing research and adaptation of vaccination strategies. Immunity following vaccination or natural infection may wane over time, raising concerns about reinfection. Research indicates that antibody levels can decrease, which may leave individuals susceptible to new infections. Regular booster vaccinations may be necessary to maintain high levels of immunity in the population and ensure sustained protection against emerging variants (91).

Implications for Public Health Strategies: The pursuit of herd immunity through vaccination carries significant implications for public health policy and strategy. Implementing comprehensive vaccination programs that prioritize access and distribution is crucial. Ensuring that vaccines are available to all segments of the population, especially marginalized communities, will help raise overall immunity levels and support the goal of herd immunity. Ongoing genomic surveillance of SARS-CoV-2 variants is essential for understanding their impact on vaccine effectiveness. This monitoring allows for timely adjustments to vaccination strategies, such as updating vaccine formulations to address new variants and implementing booster campaigns to enhance immunity. While vaccination is vital, it should be part of a multifaceted public health response. Continued adherence to preventive measures such as mask-wearing, physical distancing, and testing remains critical, particularly in areas with low vaccination rates or high transmission of variants. These strategies work in tandem with vaccination efforts to control the spread of the virus (92).

Therapeutic Strategies Against SARS-CoV-2 (Antiviral Treatments): As the COVID-19 pandemic unfolded, the need for effective therapeutic strategies to combat SARS-CoV-2 became increasingly evident. Antiviral treatments have emerged as a critical component of the therapeutic landscape for COVID-19, aimed at inhibiting the virus's replication and reducing the severity of the disease. This section provides an overview of key antiviral treatments, including remdesivir and molnupiravir, along with their mechanisms of action. Antiviral drugs are designed to target specific stages of the viral life cycle, thereby preventing the virus from replicating and spreading within the host. These treatments can be classified into several categories based on their mechanisms of action, including those that inhibit viral entry, replication, or assembly (93).

Remdesivir: Remdesivir is a nucleotide analog that interferes with viral RNA synthesis. Once inside the host cell, remdesivir is converted to its active form, which mimics adenosine triphosphate (ATP). This leads to the incorporation of remdesivir into the growing viral RNA chain during replication, resulting in premature termination of RNA transcription. By disrupting this process, remdesivir effectively hinders the ability of SARS-CoV-2 to replicate and propagate. Remdesivir was one of the first antiviral treatments to receive emergency use authorization for COVID-19. Clinical trials have demonstrated that it can reduce the time to recovery in hospitalized patients, particularly those requiring supplemental oxygen or mechanical ventilation. Its use is generally recommended for patients with severe COVID-19 symptoms, although it has also been studied in mild to moderate cases (94).

Molnupiravir: Molnupiravir operates through a different mechanism, acting as a mutagenic ribonucleoside. It introduces errors into the viral RNA during replication. When the virus attempts to replicate its genetic material, the incorporation of molnupiravir leads to an accumulation of mutations that ultimately render the virus non-viable. This error catastrophe prevents SARS-CoV2 from effectively reproducing. Molnupiravir has been granted emergency use authorization for the treatment of mild to moderate COVID-19 in patients at high risk of progressing to severe disease. Its oral formulation offers significant convenience for patients, allowing for early treatment at home, which is particularly beneficial in outpatient settings (95).

While remdesivir and molnupiravir are among the most discussed antiviral treatments, several other agents have also been evaluated for their efficacy against SARS-CoV-2. Favipiravir which is an antiviral that inhibits viral RNA polymerase, favipiravir has shown activity against various RNA viruses. Some studies suggest its potential effectiveness against COVID-19, although more research is needed to establish its clinical utility and other one is Paxlovid, This combination of nirmatrelvir and ritonavir has been authorized for treating COVID-19 in high-risk patients. Nirmatrelvir inhibits the SARS-CoV-2 protease, crucial for viral replication, while ritonavir boosts the effectiveness of nirmatrelvir by inhibiting its metabolism, increasing its concentration in the body (96).

While antiviral treatments represent a promising strategy against COVID-19, several challenges must be considered such as, the potential for viral resistance to antiviral medications is a significant concern. Mutations in the virus may diminish the effectiveness of treatments, necessitating ongoing surveillance and research to adapt therapeutic strategies accordingly. The timing of antiviral treatment initiation is crucial for maximizing effectiveness. Early intervention, preferably within the first few days of symptom onset, may lead to better outcomes, highlighting the importance of timely

diagnosis and treatment. Exploring combination therapies, where antiviral agents are used alongside other treatments such as monoclonal antibodies or anti-inflammatory drugs, may enhance therapeutic efficacy and reduce disease severity (97).

Immunomodulatory Drugs (Targeting the Immune Response to Reduce Severe Disease in COVID-19): In the fight against COVID-19, managing the immune response has become a crucial aspect of therapeutic strategies. While antiviral agents focus on inhibiting viral replication, immunomodulatory drugs aim to modulate the immune system's activity, particularly in patients experiencing severe disease characterized by hyperinflammation and a cytokine storm. This section discusses key immunomodulatory drugs, including dexamethasone and interleukin-6 (IL6) inhibitors, and their roles in mitigating severe COVID-19 outcomes (98)

The immune response to SARS-CoV-2 involves a complex interplay between innate and adaptive immunity. In mild cases, the immune system effectively controls the virus, leading to recovery. However, in severe cases, an overactive immune response can occur, resulting in excessive inflammation, tissue damage, and complications such as acute respiratory distress syndrome (ARDS). This hyperinflammatory response is often mediated by the release of pro-inflammatory cytokines, leading to the so-called "cytokine storm" (99).

Dexamethasone: Dexamethasone is a corticosteroid that exerts anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and modulating the immune response. It works by binding to glucocorticoid receptors in immune cells, leading to decreased expression of inflammatory mediators and promoting the resolution of inflammation. Dexamethasone also inhibits the activation of nuclear factor kappa B (NF-kB), a key transcription factor involved in the inflammatory response. Dexamethasone was one of the first drugs shown to reduce mortality in severe COVID-19 cases. The RECOVERY trial demonstrated that patients receiving dexamethasone had a significant reduction in mortality compared to those receiving standard care, particularly among those requiring supplemental oxygen or mechanical ventilation. Given its effectiveness, dexamethasone is now a standard treatment for hospitalized COVID-19 patients with severe disease (100).

Interleukin-6 (IL-6) Inhibitors: IL-6 is a pro-inflammatory cytokine that plays a pivotal role in the immune response and is implicated in the pathogenesis of severe COVID-19. IL-6 inhibitors, such as tocilizumab and sarilumab, target the IL-6 receptor, blocking the action of this cytokine and thereby mitigating the inflammatory response. By inhibiting IL-6 signalling, these drugs can help reduce fever, inflammatory markers, and the risk of complications associated with cytokine storms. Tocilizumab and sarilumab have been studied in clinical trials for their efficacy in treating severe COVID-19. The findings indicate that these agents may reduce the need for mechanical ventilation and improve outcomes in patients with significant inflammatory responses. The use of IL-6 inhibitors is generally recommended for hospitalized patients exhibiting rapid respiratory deterioration and elevated inflammatory markers (101).

In addition to dexamethasone and IL-6 inhibitors, other immunomodulatory therapies are being investigated for their potential benefits in treating severe COVID-19, such as 1) JAK Inhibitors, Janus kinase (JAK) inhibitors, such as baricitinib, are another class of drugs that can modulate the immune response. They work by inhibiting signaling pathways involved in the inflammatory response, leading to reduced cytokine production. Baricitinib has shown promise in combination with remdesivir for hospitalized patients with COVID-19, further underscoring the potential of targeting inflammation in treatment strategies. 2) Monoclonal Antibodies: Some monoclonal antibodies targeting inflammatory cytokines are also being studied. For example, agents that inhibit tumor necrosis factor-alpha (TNF-α) or other pro-inflammatory cytokines may offer additional therapeutic options in managing severe inflammatory responses (102).

While immunomodulatory drugs offer valuable therapeutic avenues for managing severe COVID19, there are important considerations such as, the timing of immunomodulatory treatment is critical. These drugs are most effective when administered at the right stage of disease progression typically when hyperinflammation is evident. Early use in patients without significant inflammation may compromise the immune response and increase the risk of severe infection. Immunomodulation can increase the risk of secondary infections due to dampened immune responses. Careful monitoring and assessment are necessary to balance the benefits of reducing inflammation against the potential

risks of opportunistic infections. Patient characteristics, including age, comorbidities, and the severity of the immune response, can influence the efficacy of immunomodulatory treatments. Tailoring treatment approaches to individual patient profiles is essential for optimizing outcomes (103).

Monoclonal Antibodies and Passive Immunotherapy (Neutralizing SARS-CoV-2): In the battle against COVID-19, monoclonal antibodies (mAbs) and passive immunotherapy have emerged as pivotal therapeutic strategies aimed at neutralizing SARS-CoV-2. These approaches leverage the body's immune response to enhance the effectiveness of treatments, particularly in high-risk patients or those with severe disease. This section provides an overview of convalescent plasma therapy and the development of monoclonal antibodies, highlighting their mechanisms of action, clinical applications, and challenges (104).

Passive immunotherapy involves the administration of pre-formed antibodies to individuals, providing immediate, but temporary, immunity against pathogens. This approach can be particularly beneficial in the context of emerging infectious diseases like COVID-19, where rapid therapeutic interventions are needed. There are two primary forms of passive immunotherapy utilized in the fight against SARS-CoV-2: convalescent plasma and monoclonal antibodies (105).

Convalescent Plasma: Convalescent plasma therapy involves the transfusion of plasma from individuals who have recovered from COVID-19 into patients currently battling the disease. The plasma contains antibodies against SARS-CoV-2, which can bind to the virus, neutralizing it and preventing it from infecting host cells. This passive transfer of immunity aims to bolster the recipient's immune response and accelerate recovery. Early in the pandemic, convalescent plasma was explored as a potential treatment for COVID-19. Some observational studies suggested that it might reduce the severity of illness and mortality, particularly when administered early in the course of the disease. However, subsequent randomized controlled trials yielded mixed results regarding its efficacy, leading to discussions about the timing of administration, the concentration of neutralizing antibodies in the plasma, and the patient's clinical status (106).

Monoclonal Antibodies: Monoclonal antibodies are engineered antibodies designed to specifically target and neutralize SARS-CoV-2. They are produced in the laboratory by cloning immune cells that produce a desired antibody, allowing for the generation of a consistent and potent therapeutic agent. These antibodies bind to the spike protein of the virus, preventing it from attaching to and entering human cells. Several monoclonal antibody therapies have been authorized for emergency use against COVID-19. Notable examples include 1) Casirivimab and Imdevimab, This combination targets the spike protein and has shown efficacy in reducing viral load and improving clinical outcomes in non-hospitalized patients with mild to moderate COVID19. 2) Bamlanivimab and Etesevimab: This combination also targets the spike protein and has been studied for its role in preventing disease progression in high-risk patients. Monoclonal antibodies are typically administered via infusion, and their use is recommended for patients at high risk of severe disease, particularly those who are not yet hospitalized. Clinical trials have demonstrated that these therapies can significantly reduce the risk of hospitalization and death in high-risk populations (107).

Benefits and Limitations: While both convalescent plasma and monoclonal antibodies offer promising therapeutic options, several factors must be considered such as Monoclonal antibodies can be produced more rapidly than convalescent plasma, allowing for a more consistent and standardized therapeutic product. This aspect is particularly important in the context of a pandemic. Monoclonal antibodies can be engineered for high specificity and potency against SARS-CoV-2, potentially leading to more effective neutralization compared to the broad range of antibodies present in convalescent plasma. The emergence of SARS-CoV-2 variants poses a challenge for both convalescent plasma and monoclonal antibody therapies. Some variants may evade neutralization by existing antibodies, necessitating ongoing monitoring and potential updates to therapeutic antibodies to ensure efficacy. The response to passive immunotherapy can vary based on individual patient factors, including the severity of disease, the timing of treatment, and the presence of underlying health conditions (108).

Vaccines and Immunization Strategies (Types, Mechanisms, and Effectiveness against Variants): Vaccination has been a cornerstone of the global response to the COVID-19 pandemic, significantly contributing to the control of the virus's spread and the prevention of severe disease. Several types of vaccines

have been developed, each employing different technologies and mechanisms to elicit an immune response. This section discusses the primary types of COVID-19 vaccines, their mechanisms of action, and their effectiveness against emerging variants (109).

Types of COVID-19 Vaccines

a. mRNA Vaccines

mRNA vaccines utilize messenger RNA (mRNA) to instruct cells to produce a harmless piece of the spike protein unique to SARS-CoV-2. Once this protein is expressed on the cell surface, it triggers an immune response, including the production of antibodies and activation of T-cells.

Examples:

Pfizer-BioNTech (Comirnaty): This mRNA vaccine was among the first to receive emergency use authorization. Clinical trials demonstrated high efficacy (approximately 95%) in preventing symptomatic COVID-19. It has shown effectiveness against various variants, although booster doses may be necessary to enhance protection.

Moderna (Spikevax): Similar to Pfizer-BioNTech, the Moderna vaccine utilizes mRNA technology and has shown around 94% efficacy in clinical trials. Studies indicate its ability to elicit a robust immune response against variants, though efficacy may vary (110).

b. Viral Vector Vaccines

Viral vector vaccines use a harmless virus (not the coronavirus itself) as a delivery system to carry genetic material that encodes the spike protein of SARS-CoV-2. Upon vaccination, the viral vector enters cells, leading to the production of the spike protein and triggering an immune response.

Examples:

AstraZeneca (Vaxzevria): This viral vector vaccine uses a modified version of a chimpanzee adenovirus. Clinical studies have demonstrated an efficacy rate of about 76% in preventing symptomatic COVID-19. Although some concerns were raised about its effectiveness against certain variants, it remains an important tool in vaccination campaigns worldwide.

Johnson & Johnson (Janssen): This single-dose viral vector vaccine employs a human adenovirus to deliver the spike protein. It has shown approximately 66% efficacy in preventing moderate to severe COVID-19. The vaccine has been effective against variants, and its single-dose regimen makes it particularly advantageous for mass immunization efforts (111).

c. Inactivated or Live Attenuated Vaccines

These vaccines use killed (inactivated) or weakened (live attenuated) forms of the virus to stimulate an immune response without causing disease.

The immune system recognizes these inactivated or weakened viruses as foreign, leading to the production of antibodies.

Examples:

Sinovac (CoronaVac): This inactivated virus vaccine has shown varying efficacy rates in clinical trials, typically around 50% to 84%, depending on the population and study design. It has been widely used in many countries, particularly in Asia and Latin America.

Sinopharm (BBIBP-CorV): Another inactivated virus vaccine, it has demonstrated efficacy of approximately 79%. It is part of vaccination campaigns in several countries and contributes to global vaccination efforts (112).

Effectiveness against Variants

As new variants of SARS-CoV-2 emerge, concerns about vaccine effectiveness have prompted ongoing studies and surveillance. Variants such as Delta and Omicron have shown some ability to partially evade immune responses elicited by vaccines. For instance, studies have indicated reduced neutralization capacity of antibodies against the Omicron variant compared to the original strain. However, vaccines continue to provide significant protection against severe disease and hospitalization. To enhance immunity against variants, booster doses of existing vaccines have been recommended. Clinical data suggest that booster shots can significantly increase the neutralizing antibody levels against variants, thus improving overall protection. Vaccine manufacturers are also exploring modified formulations that specifically target variants of

concern. For instance, updated versions of mRNA vaccines that incorporate sequences from variants are under investigation to improve efficacy (113).

The development of COVID-19 vaccines, including mRNA and viral vector vaccines, has been instrumental in controlling the pandemic. Each vaccine type employs unique mechanisms to stimulate an immune response, leading to the production of antibodies and T-cells. While challenges remain regarding the emergence of variants, vaccination continues to be a critical strategy in reducing transmission and preventing severe illness. Ongoing research and adaptation of vaccines will play a vital role in maintaining effective immunity against current and future variants of SARS-CoV-2 (114).

Emerging Therapeutics (New Approaches in the Fight against SARS-CoV-2): As the COVID19 pandemic has progressed, researchers and scientists have continually sought innovative methods to combat SARS-CoV-2. Beyond traditional vaccines and therapies, several emerging therapeutics are being investigated. This section highlights novel approaches, including gene therapies and nanoparticle vaccines, that may enhance our ability to prevent and treat COVID-19 (115).

Gene Therapies: Gene therapy involves the direct alteration of a person's genes to prevent or treat disease. In the context of COVID-19, gene therapies aim to bolster the immune response against SARS-CoV-2 or to inhibit the virus's ability to replicate and cause harm. Building on the success of mRNA vaccines, researchers are exploring the potential of mRNA to deliver therapeutic genes that can enhance the immune response. For instance, mRNA can be engineered to produce proteins that activate immune cells or to express factors that inhibit viral replication. CRISPR-Cas9 technology is being investigated as a method to target and disrupt the viral genome. By employing CRISPR, researchers aim to develop therapies that can recognize and cleave viral RNA, effectively preventing the virus from replicating within host cells. Although still in the early stages of research, initial studies have shown promise in animal models, and clinical trials are being planned to evaluate the safety and efficacy of these gene therapy approaches in humans (116).

Nanoparticle Vaccines: Nanoparticle vaccines utilize engineered nanoparticles to deliver antigens (substances that provoke an immune response) effectively. These nanoparticles can mimic the virus structure, enhancing the body's immune response. Nanoparticles can be designed to display multiple copies of the spike protein or other viral components on their surface, which can stimulate a robust immune response. This presentation mimics the natural infection, leading to the generation of antibodies and T-cell responses. Nanoparticles can be engineered to enhance the delivery of antigens to specific immune cells, improving the overall effectiveness of the vaccine. They may also be combined with adjuvants substances that enhance the body's immune response to the vaccine providing a more robust reaction (117).

Researchers are developing vaccines that consist of self-assembling protein nanoparticles that can present viral antigens effectively. Studies in preclinical models have indicated that these nanoparticle vaccines can induce strong immune responses. Virus-Like Particle (VLP) Vaccines are engineered to resemble viruses but do not contain any viral genetic material. These particles can elicit a strong immune response without the risk of causing disease. Examples include the development of VLP-based vaccines targeting the spike protein of SARS-CoV-2, which are currently undergoing preclinical and clinical evaluations. In addition to gene therapies and nanoparticle vaccines, researchers are investigating other novel therapeutic strategies such as, Beyond prevention, new monoclonal antibodies are being designed to target specific variants of SARS-CoV-2. These engineered antibodies may offer enhanced neutralization capacity against emerging strains. Research is focused on identifying antibodies that can neutralize multiple strains of coronaviruses. This could provide protection not just against SARS-CoV-2 but also other coronaviruses that may emerge in the future. The other strategy such as Peptide-based vaccines which use specific peptide sequences from the virus to stimulate an immune response. They may offer advantages in terms of stability and ease of production compared to traditional vaccines (118).

Challenges in SARS-CoV-2 Research: The rapid emergence of SARS-CoV-2 variants poses a significant challenge in vaccine effectiveness and disease management. Variants such as Delta and Omicron have shown increased transmissibility and, in some cases, partial resistance to neutralization by antibodies generated from previous infections or vaccinations. This evolution necessitates ongoing surveillance and potential updates to vaccines to maintain their effectiveness. The need for booster doses to enhance immunity against

these variants highlights the dynamic nature of viral evolution and the corresponding adaptability required in vaccine development. Despite initial robust immune responses following vaccination or natural infection, instances of reinfection have been reported. The waning of immunity over time complicates the understanding of long-term protection against SARS-CoV-2 (119).

Ongoing research is needed to better characterize the longevity of immune responses and the factors that contribute to reinfection. This includes investigating the roles of different immune cells, such as memory B cells and T cells, and how they respond to variants. The complexities of the immune response to SARS-CoV-2 are still being unravelled. For instance, the role of cellular immunity in providing protection against severe disease is not fully understood. Understanding the nuances of the immune system's response, how it reacts to variants, the threshold for protection, and the interplay between humoral and cellular immunity remains a critical area of research. This knowledge will inform vaccination strategies and therapeutic interventions (120).

Future of Therapeutic Strategies: In response to ongoing challenges posed by SARS-CoV-2, several new therapeutic avenues are being explored. Beyond existing antiviral treatments, research into novel compounds that can inhibit viral replication is essential. Drugs targeting different stages of the viral lifecycle, including entry inhibitors and polymerase inhibitors, are under investigation. As understanding of the immune response evolves, the development of therapies that can modulate the immune response, rather than simply suppress it, could be beneficial. This includes strategies to enhance the body's natural defences against the virus while minimizing the risk of severe inflammatory responses.

Given the complexity of SARS-CoV-2 and the immune response it elicits, a multi-targeted approach is increasingly seen as vital for effective management of COVID-19. Just as combination antiretroviral therapy is standard in HIV treatment, similar strategies may be needed for COVID-19. Combining antiviral treatments with immune modulators or monoclonal antibodies could provide a more comprehensive approach to controlling the disease. Future strategies may also involve personalized medicine approaches, tailoring treatment based on individual immune responses, genetic backgrounds, and specific variants involved in the infection (121).

The journey to effectively combat SARS-CoV-2 is fraught with challenges, from the emergence of new variants and issues surrounding reinfection to the evolving understanding of immune protection. However, the landscape of therapeutic strategies is equally promising, with ongoing research focused on innovative treatments and multi-targeted approaches. Addressing these challenges and harnessing new opportunities will be crucial for enhancing global health responses and mitigating the impact of COVID-19, both now and in the future (122).

Lessons Learned from SARS-CoV-2 for Future Outbreaks: The COVID-19 pandemic has had a profound impact on global health systems, economies, and societies. As the world begins to recover, it is crucial to reflect on the lessons learned from the SARS-CoV-2 experience to enhance preparedness for future pandemics. This section outlines key insights gained during the COVID19 crisis and their implications for future outbreak readiness. One of the most critical lessons from the COVID-19 pandemic is the importance of robust surveillance systems. Timely and effective monitoring of respiratory diseases can facilitate early detection of outbreaks and help contain the spread of infectious agents. Strengthening international collaboration in data sharing and surveillance can improve the global response to emerging infectious diseases. Initiatives like the Global Health Security Agenda (GHSA) highlight the need for coordinated efforts in surveillance, research, and resource allocation (123).

The pandemic revealed vulnerabilities in healthcare systems worldwide. Increasing healthcare capacity, including hospital infrastructure, medical supplies, and healthcare workforce training, is vital for managing surges in patients during pandemics. Countries must prioritize investment in public health infrastructure, ensuring that health systems are equipped to handle a variety of challenges posed by infectious diseases, including the availability of personal protective equipment (PPE) and ventilators. The rapid development of effective COVID-19 vaccines, such as those using mRNA technology, showcased the potential for accelerated research and development in response to emerging infectious diseases (124). Increased funding for research and the establishment of frameworks for expedited approval processes can enhance the speed of vaccine and therapeutic development during future outbreaks. Clear and transparent communication from

public health authorities is critical during a pandemic. Misinformation can spread rapidly and undermine public trust and adherence to health guidelines. Effective communication strategies should involve engaging communities and stakeholders to ensure accurate dissemination of information and address public concerns, fostering a collaborative approach to health responses. The COVID-19 pandemic highlighted significant inequities in access to healthcare, particularly regarding vaccines and treatments. Future pandemic preparedness must prioritize equitable access to healthcare resources for all populations. Strengthening initiatives that ensure equitable distribution of vaccines and treatments, such as COVAX, can help mitigate disparities in healthcare access during global health emergencies (125).

Effective pandemic response requires coordination across multiple sectors, including public health, government, private industry, and community organizations. Developing comprehensive pandemic preparedness plans that involve all stakeholders can create a unified approach to outbreak response, ensuring that resources are mobilized efficiently and effectively. The emergence of zoonotic diseases like SARS-CoV-2 underscores the need for a One Health approach, integrating human, animal, and environmental health. Enhancing surveillance and preventive strategies in both animal and environmental health can reduce the risk of future zoonotic spillovers and improve overall public health preparedness (126).

The COVID-19 pandemic, driven by the emergence of SARS-CoV-2, has profoundly reshaped the global health landscape. As we reflect on the extensive research conducted over the past few years, several key insights into the biology of the virus, the immune response it elicits, and the therapeutic strategies developed to combat it emerge. The structural and genomic characteristics of SARS-CoV-2 have been fundamental to our understanding of its pathogenicity and transmission. The spike (S) protein's role in viral entry via the ACE2 receptor has highlighted potential targets for therapeutic intervention, including vaccines and monoclonal antibodies. Comparative studies with related coronaviruses, such as SARS-CoV and MERS-CoV, have provided context for understanding SARS-CoV-2's unique attributes and behavior. The immune response to SARS-CoV-2 encompasses both innate and adaptive mechanisms. The initial innate immune response involves the release of interferons and inflammatory cytokines, setting the stage for a robust adaptive response characterized by T-cell and B-cell activation. However, the virus's ability to evade certain immune detection strategies has complicated the landscape, leading to ongoing research into how these immune responses evolve over time and the implications for long-term immunity.

The rapid development of various therapeutic approaches, including antiviral drugs, immunomodulatory therapies, and monoclonal antibodies, reflects a significant advancement in our ability to manage COVID-19. Vaccines, particularly mRNA-based ones, have proven effective in reducing severe disease and hospitalization, yet the emergence of variants necessitates continuous adaptation of our therapeutic arsenal. The pursuit of new strategies, such as nanoparticle vaccines and gene therapies, further underscores the innovative spirit of the scientific community in addressing evolving challenges. As we continue to navigate the complexities of SARS-CoV-2 and its impact on global health, ongoing research and collaboration remain paramount. Understanding the virus's biology, the nuances of the immune response, and the effectiveness of therapeutic strategies will be essential for developing comprehensive public health responses and improving future pandemic preparedness. The experiences gained from this pandemic highlight the importance of a coordinated global effort in addressing health threats. Lessons learned about the need for robust healthcare systems, equitable access to medical resources, and clear communication with the public will serve as a foundation for future responses to emerging infectious diseases.

In conclusion, while the challenges posed by SARS-CoV-2 are significant, the resilience and ingenuity of the scientific community, alongside global cooperation, pave the way for enhanced understanding and mitigation of the impact of such pathogens on public health. As we move forward, continued investment in research, public health infrastructure, and international collaboration will be essential to safeguard against future outbreaks and ensure a healthier, more resilient world.

Author Contributions

Vishwakarma Bhanupratap: Investigation, formal analysis, writing—original draft. Harshada Kulaye: Validation, methodology, writing—reviewing. Shruti Tiwari:—Formal analysis, writing—review and editing.

Shizan Alam: Investigation, writing—reviewing. Shivani Pandey: Resources, investigation writing—reviewing. Sonali Joshi: Validation, formal analysis, writing—reviewing.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethical Approval Not applicable.

Consent to Participate Not applicable.

Consent to Publish Not applicable.

Conflict of Interest The authors declare no competing interests.

References

1. Aguilera, B., Donya, R. S., Vélez, C.-M., Kapiriri, L., Abelson, J., Nouvet, E., Danis, M., Goold, S., Williams, I., & Noorulhuda, M. (2024). Stakeholder participation in the COVID-19 pandemic preparedness and response plans: A synthesis of findings from 70 countries. Health Policy, 142, 105013. https://doi.org/10.1016/j.healthpol.2024.105013
2. Ahmadi, S., Bazargan, M., Elahi, R., & Esmaeilzadeh, A. (2023). Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches. Molecular immunology, 156, 10–19. https://doi.org/10.1016/j.molimm.2022.11.020
3. Alaa Alnefaie, Sarah Albogami, Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective, Saudi Pharmaceutical Journal, Volume28, Issue11, 2020, Pages 1333-1352, ISSN 1319-0164, https://doi.org/10.1016/j.jsps.2020.08.024 .
4. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Helper T Cells and Lymphocyte Activation. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26827/
5. Aledo-Serrano, A., Gil-Nagel, A., Isla, J., Mingorance, A., Mendez-Hermida, F., & Hernandez-Alcoceba, R. (2021). Gene therapies and COVID-19 vaccines: a necessary discussion in relation with viral vector-based approaches. Orphanet journal of rare diseases, 16(1), 316. https://doi.org/10.1186/s13023-021-01958-3
6. Alhamlan, F. S., & Al-Qahtani, A. A. (2025). SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies. International journal of molecular sciences, 26(3), 1263. https://doi.org/10.3390/ijms26031263
7. Alijotas-Reig, J., Esteve-Valverde, E., Belizna, C., Selva-O'Callaghan, A., Pardos-Gea, J., Quintana, A., Mekinian, A., Anunciacion-Llunell, A., & Miró-Mur, F. (2020). Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmunity reviews, 19(7), 102569. https://doi.org/10.1016/j.autrev.2020.102569
8. Al-Momani, H., Aolymat, I., Almasri, M., Mahmoud, S. A., & Mashal, S. (2023). Prevalence of gastro-intestinal symptoms among COVID-19 patients and the association with disease clinical outcomes. Future science OA, 9(5), FSO858. https://doi.org/10.2144/fsoa-2023-0040
9. Ashraf, U. M., Abokor, A. A., Edwards, J. M., Waigi, E. W., Royfman, R. S., Hasan, S. A., Smedlund, K. B., Hardy, A. M. G., Chakravarti, R., & Koch, L. G. (2021). SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiological genomics, 53(2), 51–60. https://doi.org/10.1152/physiolgenomics.00087.2020
10. Atef, S., Al Hosani, F., AbdelWareth, L., Al-Rifai, R. H., Abuyadek, R., Jabari, A., Ali, R., Altrabulsi, B., Dunachie, S., Alatoom, A., & Donnelly, J. G. (2023). Susceptibility to reinfection with SARS-CoV-2 virus relative to existing antibody concentrations and T cell response. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 131, 100–110. https://doi.org/10.1016/j.ijid.2023.01.006
11. Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M. C., O'Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020). Immune response to SARS-CoV2 and mechanisms of immunopathological changes in COVID-19.

Allergy, 75(7), 1564–1581. https://doi.org/10.1111/all.14364
12. Azuma, K., Yanagi, U., Kagi, N., Kim, H., Ogata, M., & Hayashi, M. (2020). Environmental factors involved in SARS-CoV-2 transmission: effect and role of indoor environmental quality in the strategy for COVID-19 infection control. Environmental health and preventive medicine, 25(1), 66. https://doi.org/10.1186/s12199-020-00904-2
13. Bai, Z., Cao, Y., Liu, W., & Li, J. (2021). The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses, 13(6), 1115. https://doi.org/10.3390/v13061115
14. BalcioĞlu, B. K., Denİzcİ ÖncÜ, M., ÖztÜrk, H. Ü., YÜcel, F., Kaya, F., Serhatli, M., ÜlbeĞİ Polat, H., TekİN, Ş., & Özdemİr Bahadir, A. (2020). SARS-CoV-2 neutralizing antibody development strategies. Turkish journal of biology = Turk biyoloji dergisi, 44(3), 203–214. https://doi.org/10.3906/biy-2005-91
15. Barros de Lima, G., Nencioni, E., Thimoteo, F., Perea, C., Pinto, R. F. A., & Sasaki, S. D. (2025). TMPRSS2 as a Key Player in Viral Pathogenesis: Influenza and Coronaviruses. Biomolecules, 15(1), 75. https://doi.org/10.3390/biom15010075
16. Beyer, D. K., & Forero, A. (2022). Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. Journal of molecular biology, 434(6), 167265. https://doi.org/10.1016/j.jmb.2021.167265
17. Borges do Nascimento, I. J., Pizarro, A. B., Almeida, J. M., Azzopardi-Muscat, N., Gonçalves, M. A., Björklund, M., & Novillo-Ortiz, D. (2022). Infodemics and health misinformation: a systematic review of reviews. Bulletin of the World Health Organization, 100(9), 544–561. https://doi.org/10.2471/BLT.21.287654
18. Buchy, P., Buisson, Y., Cintra, O., Dwyer, D. E., Nissen, M., Ortiz de Lejarazu, R., & Petersen, E. (2021). COVID-19 pandemic: Lessons learned from more than a century of pandemics and current vaccine development for pandemic control. International Journal of Infectious Diseases, 112, 300–317. https://doi.org/10.1016/j.ijid.2021.09.045
19. Bullen, M., Heriot, G. S., & Jamrozik, E. (2023). Herd immunity, vaccination and moral obligation. Journal of medical ethics, 49(9), 636–641. https://doi.org/10.1136/jme-2022108485
20. Candido, K. L., Eich, C. R., de Fariña, L. O., Kadowaki, M. K., da Conceição Silva, J. L., Maller, A., & Simão, R. C. G. (2022). Spike protein of SARS-CoV-2 variants: a brief review and practical implications. Brazilian journal of microbiology: [publication of the Brazilian Society for Microbiology], 53(3), 1133–1157. https://doi.org/10.1007/s42770-022-00743-z
21. Cano RLE, Lopera HDE. Introduction to T and B lymphocytes. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, *et al.,* editors. Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 5.
22. Chatterjee, S., Bhattacharya, M., Dhama, K., Lee, S. S., & Chakraborty, C. (2023). Molnupiravir's mechanism of action drives "error catastrophe" in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus. Molecular therapy. Nucleic acids, 33, 49–52. https://doi.org/10.1016/j.omtn.2023.06.006
23. Chattopadhyay, S., Chen, J. Y., Chen, H. W., & Hu, C. J. (2017). Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation. Nanotheranostics, 1(3), 244– 260. https://doi.org/10.7150/ntno.19796
24. Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Vineela Nalla, L., & Koradia, K. (2023). mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!. Vaccines, 11(3), 507. https://doi.org/10.3390/vaccines11030507
25. Chen, B., Julg, B., Mohandas, S., Bradfute, S. B., & RECOVER Mechanistic Pathways Task Force (2023). Viral persistence, reactivation, and mechanisms of long COVID. eLife, 12, e86015. https://doi.org/10.7554/eLife.86015
26. Chen, P., Wu, M., He, Y., Jiang, B., & He, M. L. (2023). Metabolic alterations upon SARSCoV-2 infection and potential therapeutic targets against coronavirus infection. Signal transduction and targeted therapy, 8(1), 237. https://doi.org/10.1038/s41392-023-01510-8
27. Chen, Q., Zhang, J., Wang, P., & Zhang, Z. (2022). The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. iScience, 25(10), 105044. https://doi.org/10.1016/j.isci.2022.105044
28. Cimolai N. (2021). Passive Immunity Should and Will Work for COVID-19 for Some Patients. Clinical hematology international, 3(2), 47–68. https://doi.org/10.2991/chi.k.210328.001
29. Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L.

(2020). SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine & growth factor reviews, 54, 62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001

30. Coutinho, A. E., & Chapman, K. E. (2011). The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Molecular and cellular endocrinology, 335(1), 2–13. https://doi.org/10.1016/j.mce.2010.04.005
31. Dalskov, L., Gad, H. H., & Hartmann, R. (2023). Viral recognition and the antiviral interferon response. The EMBO journal, 42(14), e112907. https://doi.org/10.15252/embj.2022112907
32. Datta, P. K., Liu, F., Fischer, T., Rappaport, J., & Qin, X. (2020). SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics, 10(16), 7448–7464. https://doi.org/10.7150/thno.48076
33. Dhawan, M., Priyanka, Parmar, M., Angural, S., & Choudhary, O. P. (2022). Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks. International journal of surgery (London, England), 97, 106204. https://doi.org/10.1016/j.ijsu.2021.106204
34. Du, P., Geng, J., Wang, F., Chen, X., Huang, Z., & Wang, Y. (2021). Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. International journal of medical sciences, 18(6), 1356–1362. https://doi.org/10.7150/ijms.53564
35. Elekhnawy, E., Kamar, A.A. & Sonbol, F. Present and future treatment strategies for coronavirus disease 2019. Futur J Pharm Sci 7, 84 (2021). https://doi.org/10.1186/s43094-02100238-y
36. Farrukh, H., El-Sayes, N., & Mossman, K. (2021). Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells. International journal of molecular sciences, 22(9), 4893. https://doi.org/10.3390/ijms22094893
37. Galati, D., Zanotta, S., Capitelli, L., & Bocchino, M. (2022). A bird's eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines. Allergy, 77(1), 100–110. https://doi.org/10.1111/all.15004
38. Ghattas, M., Dwivedi, G., Lavertu, M., & Alameh, M. G. (2021). Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines, 9(12), 1490. https://doi.org/10.3390/vaccines9121490
39. Ghildiyal, T., Rai, N., Mishra Rawat, J., Singh, M., Anand, J., Pant, G., Kumar, G., & Shidiki, A. (2024). Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants. Journal of immunology research, 2024, 9125398. https://doi.org/10.1155/2024/9125398
40. Gong, W., Parkkila, S., Wu, X., & Aspatwar, A. (2022). SARS-CoV-2 variants and COVID19 vaccines: Current challenges and future strategies. International Reviews of Immunology, 42(6), 393–414. https://doi.org/10.1080/08830185.2022.2079642
41. Gonzalez-Garcia, P., Fiorillo Moreno, O., Zarate Peñata, E., Calderon-Villalba, A., Pacheco Lugo, L., Acosta Hoyos, A., Villarreal Camacho, J. L., Navarro Quiroz, R., Pacheco Londoño, L., Aroca Martinez, G., Moares, N., Gabucio, A., Fernandez-Ponce, C., Garcia-Cozar, F., & Navarro Quiroz, E. (2023). From Cell to Symptoms: The Role of SARS-CoV-2 Cytopathic Effects in the Pathogenesis of COVID-19 and Long COVID. International journal of molecular sciences, 24(9), 8290. https://doi.org/10.3390/ijms24098290
42. Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020). Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. The Journal of biological chemistry, 295(20), 6785–6797. https://doi.org/10.1074/jbc.RA120.013679
43. Gorkhali, R., Koirala, P., Rijal, S., Mainali, A., Baral, A., & Bhattarai, H. K. (2021). Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins. Bioinformatics and biology insights, 15, 11779322211025876. https://doi.org/10.1177/11779322211025876
44. Goyal, R., Gautam, R. K., Chopra, H., Dubey, A. K., Singla, R. K., Rayan, R. A., & Kamal, M. A. (2022). Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV. EXCLI journal, 21, 1245–1272. https://doi.org/10.17179/excli2022-5355
45. Guo, W., Fu, Y., Jia, R., Guo, Z., Su, C., Li, J., Zhao, X., Jin, Y., Li, P., Fan, J., Zhang, C., Qu, P., Cui, H., Gao, S., Cheng, H., Li, J., Li, X., Lu, B., Xu, X., & Wang, Z. (2022). Visualization of the infection risk assessment of SARS-CoV-2 through aerosol and surface transmission in a negative-

pressure ward. Environment international, 162, 107153. https://doi.org/10.1016/j.envint.2022.107153

46. Haiyue Huang, Hun Park, Yihan Liu, Jiaxing Huang, On-Mask Chemical Modulation of Respiratory Droplets, Matter, Volume 3, Issue 5, 2020, Pages 1791-1810, ISSN 2590-2385, https://doi.org/10.1016/j.matt.2020.10.012.
47. Harrison, A. G., Lin, T., & Wang, P. (2020). Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends in immunology, 41(12), 1100–1115. https://doi.org/10.1016/j.it.2020.10.004
48. Hassan, S. S., Choudhury, P. P., Dayhoff, G. W., 2nd, Aljabali, A. A. A., Uhal, B. D., Lundstrom,K., Rezaei, N., Pizzol, D., Adadi, P., Lal, A., Soares, A., Mohamed Abd El-Aziz, T., Brufsky, A. M., Azad, G. K., Sherchan, S. P., Baetas-da-Cruz, W., Takayama, K., Serrano-Aroca, Ã., Chauhan, G., Palu, G., … Uversky, V. N. (2022). The importance of accessory protein variants in the pathogenicity of SARS-CoV-2. Archives of biochemistry and biophysics, 717, 109124. https://doi.org/10.1016/j.abb.2022.109124
49. Hu, B., Guo, H., Zhou, P., & Shi, Z. L. (2021). Characteristics of SARS-CoV-2 and COVID19. Nature reviews. Microbiology, 19(3), 141–154. https://doi.org/10.1038/s41579-02000459-7
50. Huang, Y., Yang, C., Xu, X. F., Xu, W., & Liu, S. W. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID19. Acta pharmacologica Sinica, 41(9), 1141–1149. https://doi.org/10.1038/s41401-020-04854
51. Islam, M. A. (2023). A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety. Infectious Medicine, 2(4), 247–261. https://doi.org/10.1016/j.imj.2023.08.005
52. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. Immunological memory. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27158/
53. Kane, B. A., Bryant, K. J., McNeil, H. P., & Tedla, N. T. (2014). Termination of immune activation: an essential component of healthy host immune responses. Journal of innate immunity, 6(6), 727–738. https://doi.org/10.1159/000363449
54. Kany, S., Vollrath, J. T., & Relja, B. (2019). Cytokines in Inflammatory Disease. International journal of molecular sciences, 20(23), 6008. https://doi.org/10.3390/ijms20236008
55. Katiyar, H., Arduini, A., Li, Y., & Liang, C. (2024). SARS-CoV-2 Assembly: Gaining Infectivity and Beyond. Viruses, 16(11), 1648. https://doi.org/10.3390/v16111648
56. Kaushik, A., Fomicheva, J., Boonstra, N., Faber, E., Gupta, S., & Kest, H. (2025). Pediatric Vaccine Hesitancy in the United States-The Growing Problem and Strategies for Management Including Motivational Interviewing. Vaccines, 13(2), 115. https://doi.org/10.3390/vaccines13020115
57. Khaledi, M., Sameni, F., Yahyazade, S., Radandish, M., Owlia, P., Bagheri, N., Afkhami, H., Mahjoor, M., Esmaelpour, Z., Kohansal, M., & Aghaei, F. (2022). COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. Frontiers in medicine, 9, 961027. https://doi.org/10.3389/fmed.2022.961027
58. Khoshnood, S., Ghanavati, R., Shirani, M., Ghahramanpour, H., Sholeh, M., Shariati, A., Sadeghifard, N., & Heidary, M. (2022). Viral vector and nucleic acid vaccines against COVID-19: A narrative review. Frontiers in microbiology, 13, 984536. https://doi.org/10.3389/fmicb.2022.984536
59. Kindler, E., Thiel, V., & Weber, F. (2016). Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Advances in virus research, 96, 219–243. https://doi.org/10.1016/bs.aivir.2016.08.006
60. Kopańska, M., Barnaś, E., Błajda, J., Kuduk, B., Łagowska, A., & Banaś-Ząbczyk, A. (2022). Effects of SARS-CoV-2 Inflammation on Selected Organ Systems of the Human Body. International journal of molecular sciences, 23(8), 4178. https://doi.org/10.3390/ijms23084178
61. Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., & Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial agents, 55(3), 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
62. Le, K., Kannappan, S., Kim, T., Lee, J. H., Lee, H. R., & Kim, K. K. (2023). Structural understanding of SARS-CoV-2 virus entry to host cells. Frontiers in molecular biosciences, 10, 1288686. https://doi.org/10.3389/fmolb.2023.1288686

63. Legrand, M., Bell, S., Forni, L., Joannidis, M., Koyner, J. L., Liu, K., & Cantaluppi, V. (2021). Pathophysiology of COVID-19-associated acute kidney injury. Nature reviews. Nephrology, 17(11), 751–764. https://doi.org/10.1038/s41581-021-00452-0
64. Li F. (2016). Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual review of virology, 3(1), 237–261. https://doi.org/10.1146/annurev-virology-110615-042301
65. Liu, Q., Chi, S., Dmytruk, K., Dmytruk, O., & Tan, S. (2022). Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. Viruses, 14(7), 1349. https://doi.org/10.3390/v14071349
66. Manfrini, N., Notarbartolo, S., Grifantini, R., & Pesce, E. (2024). SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination. Antibodies (Basel, Switzerland), 13(1), 13. https://doi.org/10.3390/antib13010013
67. Meng, J., Li, R., Zhang, Z., Wang, J., Huang, Q., Nie, D., Fan, K., Guo, W., Zhao, Z., & Han, Z. (2022). A Review of Potential Therapeutic Strategies for COVID-19. Viruses, 14(11), 2346. https://doi.org/10.3390/v14112346
68. Meyerowitz, E. A., & Richterman, A. (2022). SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. Infectious disease clinics of North America, 36(2), 267–293. https://doi.org/10.1016/j.idc.2022.01.007
69. Milne, G., Hames, T., Scotton, C., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021). Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? The Lancet. Respiratory medicine, 9(12), 1450–1466. https://doi.org/10.1016/S22132600(21)00407-0
70. Minkoff, J.M., tenOever, B. Innate immune evasion strategies of SARS-CoV-2. Nat Rev Microbiol 21, 178–194 (2023). https://doi.org/10.1038/s41579-022-00839-1
71. Morais da Silva, M., Lira de Lucena, A. S., Paiva Júnior, S. S. L., Florêncio De Carvalho, V. M., Santana de Oliveira, P. S., da Rosa, M. M., Barreto de Melo Rego, M. J., Pitta, M. G. D. R., & Pereira, M. C. (2022). Cell death mechanisms involved in cell injury caused by SARSCoV-2. Reviews in medical virology, 32(3), e2292. https://doi.org/10.1002/rmv.2292
72. Morales-Hernández, S., Ugidos-Damboriena, N., & López-Sagaseta, J. (2022). SelfAssembling Protein Nanoparticles in the Design of Vaccines: 2022 Update. Vaccines, 10(9), 1447. https://doi.org/10.3390/vaccines10091447
73. Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020). Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochimica et biophysica acta. Molecular basis of disease, 1866(10), 165878. https://doi.org/10.1016/j.bbadis.2020.165878
74. Nunes, M. C., Thommes, E., Fröhlich, H., Flahault, A., Arino, J., Baguelin, M., Biggerstaff, M., Bizel-Bizellot, G., Borchering, R., Cacciapaglia, G., Cauchemez, S., Barbier-Chebbah, A., Claussen, C., Choirat, C., Cojocaru, M., Commaille-Chapus, C., Hon, C., Kong, J., Lambert, N., Lauer, K. B., Coudeville, L. (2024). Redefining pandemic preparedness: Multidisciplinary insights from the CERP modelling workshop in infectious diseases, workshop report. Infectious Disease Modelling, 9(2), 501–518. https://doi.org/10.1016/j.idm.2024.02.008
75. Okuyama R. (2023). mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID19 Vaccines: Technologies, Ecosystem, and Future Directions. Vaccines, 11(12), 1737. https://doi.org/10.3390/vaccines11121737
76. Onakpoya, I. J., Heneghan, C. J., Spencer, E. A., Brassey, J., Plüddemann, A., Evans, D. H., Conly, J. M., & Jefferson, T. (2021). SARS-CoV-2 and the role of fomite transmission: a systematic review. F1000Research, 10, 233. https://doi.org/10.12688/f1000research.51590.3
77. Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R., & Ioannidis, J. P. A. (2022). SARSCoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environmental research, 209, 112911. https://doi.org/10.1016/j.envres.2022.112911
78. Primorac, D., Vrdoljak, K., Brlek, P., Pavelić, E., Molnar, V., Matišić, V., Erceg Ivkošić, I., & Parčina, M. (2022). Adaptive Immune Responses and Immunity to SARS-CoV-2. Frontiers in immunology, 13, 848582. https://doi.org/10.3389/fimmu.2022.848582
79. Rabaan, A. A., Smajlović, S., Tombuloglu, H., Ćordić, S., Hajdarević, A., Kudić, N., Al Mutai, A., Turkistani, S. A., Al-Ahmed, S. H., Al-Zaki, N. A., Al Marshood, M. J., Alfaraj, A. H., Alhumaid,

S., & Al-Suhaimi, E. (2023). SARS-CoV-2 infection and multi-organ system damage: A review. Biomolecules & biomedicine, 23(1), 37–52. https://doi.org/10.17305/bjbms.2022.7762

80. Rahmah, L., Abarikwu, S. O., Arero, A. G., Essouma, M., Jibril, A. T., Fal, A., Flisiak, R., Makuku, R., Marquez, L., Mohamed, K., Ndow, L., Zarębska-Michaluk, D., Rezaei, N., & Rzymski, P. (2022). Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacological reports: PR, 74(6), 1255–1278. https://doi.org/10.1007/s43440-022-003887
81. Rampersad, S., & Tennant, P. (2018). Replication and Expression Strategies of Viruses. Viruses, 55–82. https://doi.org/10.1016/B978-0-12-811257-1.00003-6
82. Rasool, G., Khan, W. A., Khan, A. M., Riaz, M., Abbas, M., Rehman, A. U., Irshad, S., & Ahmad, S. (2024). COVID-19: A threat to the respiratory system. International journal of immunopathology and pharmacology, 38, 3946320241310307. https://doi.org/10.1177/03946320241310307
83. Rodrigues, C. M. C., & Plotkin, S. A. (2020). Impact of Vaccines; Health, Economic and Social Perspectives. Frontiers in microbiology, 11, 1526. https://doi.org/10.3389/fmicb.2020.01526
84. Rubio-Casillas, A., Redwan, E. M., & Uversky, V. N. (2022). SARS-CoV-2: A Master of Immune Evasion. Biomedicines, 10(6), 1339. https://doi.org/10.3390/biomedicines10061339
85. Sacchi, A., Giannessi, F., Sabatini, A., Percario, Z. A., & Affabris, E. (2023). SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?. International journal of molecular sciences, 24(11), 9353. https://doi.org/10.3390/ijms24119353
86. Sayahinouri, M., Mashayekhi Firouz, S., Ebrahimi Sadrabadi, A., Masoudnia, M., Abdolahi, M., Jafarzadeh, F., Nouripour, M., Mirzazadeh, S., Zangeneh, N., Jalili, A., & Aghdami, N. (2023). Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics. BioImpacts: BI, 13(2), 159–179. https://doi.org/10.34172/bi.2023.23839
87. Schiuma, G., Beltrami, S., Bortolotti, D., Rizzo, S., & Rizzo, R. (2022). Innate Immune Response in SARS-CoV-2 Infection. Microorganisms, 10(3), 501. https://doi.org/10.3390/microorganisms10030501
88. Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: current knowledge. Virology journal, 16(1), 69. https://doi.org/10.1186/s12985-019-1182-0
89. Shenoy S. (2021). SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review. World journal of critical care medicine, 10(4), 132–150. https://doi.org/10.5492/wjccm.v10.i4.132
90. Silva, M. J. A., Ribeiro, L. R., Lima, K. V. B., & Lima, L. N. G. C. (2022). Adaptive immunity to SARS-CoV-2 infection: A systematic review. Frontiers in immunology, 13, 1001198. https://doi.org/10.3389/fimmu.2022.1001198
91. Speiser, D. E., & Bachmann, M. F. (2020). COVID-19: Mechanisms of Vaccination and Immunity. Vaccines, 8(3), 404. https://doi.org/10.3390/vaccines8030404
92. Sunagar, R., Singh, A., & Kumar, S. (2023). SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines, 11(4), 849. https://doi.org/10.3390/vaccines11040849
93. Tang, S., Mao, Y., Jones, R. M., Tan, Q., Ji, J. S., Li, N., Shen, J., Lv, Y., Pan, L., Ding, P., Wang, X., Wang, Y., MacIntyre, C. R., & Shi, X. (2020). Aerosol transmission of SARS-CoV2? Evidence, prevention and control. Environment international, 144, 106039. https://doi.org/10.1016/j.envint.2020.106039
94. Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021). Neutralizing monoclonal antibodies for treatment of COVID-19. Nature reviews. Immunology, 21(6), 382–393. https://doi.org/10.1038/s41577-021-00542-x
95. Te Velthuis, A. J., Arnold, J. J., Cameron, C. E., van den Worm, S. H., & Snijder, E. J. (2010). The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic acids research, 38(1), 203–214. https://doi.org/10.1093/nar/gkp904
96. Thakur, S., Sasi, S., Pillai, S. G., Nag, A., Shukla, D., Singhal, R., Phalke, S., & Velu, G. S. K. (2022). SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. Frontiers in medicine, 9, 815389. https://doi.org/10.3389/fmed.2022.815389
97. Tharayil, A., Rajakumari, R., Mozetic, M., Primc, G., & Thomas, S. (2021). Contact transmission of SARS-CoV-2 on fomite surfaces: surface survival

and risk reduction. Interface focus, 12(1), 20210042. https://doi.org/10.1098/rsfs.2021.0042
98. Thomas Craig, K. J., Rizvi, R., Willis, V. C., Kassler, W. J., & Jackson, G. P. (2021). Effectiveness of Contact Tracing for Viral Disease Mitigation and Suppression: Evidence-Based Review. JMIR public health and surveillance, 7(10), e32468. https://doi.org/10.2196/32468
99. Tobian, A. A. R., Cohn, C. S., & Shaz, B. H. (2022). COVID-19 convalescent plasma. Blood, 140(3), 196–207. https://doi.org/10.1182/blood.2021012248
100. Tyagi, K., Rai, P., Gautam, A., Kaur, H., Kapoor, S., Suttee, A., Jaiswal, P. K., Sharma, A., Singh, G., & Barnwal, R. P. (2023). Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders. European journal of medical research, 28(1), 307. https://doi.org/10.1186/s40001-023-01293-2
101. V'kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. Nature reviews. Microbiology, 19(3), 155–170. https://doi.org/10.1038/s41579-020-00468-6
102. Vangeel, L., Chiu, W., De Jonghe, S., Maes, P., Slechten, B., Raymenants, J., André, E., Leyssen, P., Neyts, J., & Jochmans, D. (2022). Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral research, 198, 105252. https://doi.org/10.1016/j.antiviral.2022.105252
103. Varghese, P. M., Tsolaki, A. G., Yasmin, H., Shastri, A., Ferluga, J., Vatish, M., Madan, T., & Kishore, U. (2020). Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 225(6), 152008. https://doi.org/10.1016/j.imbio.2020.152008
104. Velavan, T. P., Pallerla, S. R., Rüter, J., Augustin, Y., Kremsner, P. G., Krishna, S., & Meyer, C. G. (2021). Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine, 72, 103629. https://doi.org/10.1016/j.ebiom.2021.103629
105. Velikova, T., Valkov, H., Aleksandrova, A., Peshevska-Sekulovska, M., Sekulovski, M., & Shumnalieva, R. (2024). Harnessing immunity: Immunomodulatory therapies in COVID-19. World journal of virology, 13(2), 92521. https://doi.org/10.5501/wjv.v13.i2.92521
106. Villanueva, R. A., Rouillé, Y., & Dubuisson, J. (2005). Interactions between virus proteins and host cell membranes during the viral life cycle. International review of cytology, 245, 171– 244. https://doi.org/10.1016/S0074-7696(05)45006-8
107. Vinayagam, S., & Sattu, K. (2020). SARS-CoV-2 and coagulation disorders in different organs. Life sciences, 260, 118431. https://doi.org/10.1016/j.lfs.2020.118431
108. Vivekanandhan, K., Shanmugam, P., Barabadi, H., Arumugam, V., Daniel Raj Daniel Paul Raj, D., Sivasubramanian, M., Ramasamy, S., Anand, K., Boomi, P., Chandrasekaran, B., Arokiyaraj, S., & Saravanan, M. (2021). Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives. Frontiers in molecular biosciences, 8, 604447. https://doi.org/10.3389/fmolb.2021.604447
109. Walker, F. C., Sridhar, P. R., & Baldridge, M. T. (2021). Differential roles of interferons in innate responses to mucosal viral infections. Trends in immunology, 42(11), 1009–1023. https://doi.org/10.1016/j.it.2021.09.003
110. Wang, C., Zhou, X., Wang, M., & Chen, X. (2020). The Impact of SARS-CoV-2 on the Human Immune System and Microbiome. Infectious microbes & diseases, 3(1), 14–21. https://doi.org/10.1097/IM9.0000000000000045
111. Wang, L., Nicols, A., Turtle, L., Richter, A., Duncan, C. J., Dunachie, S. J., Klenerman, P., & Payne, R. P. (2023). T cell immune memory after covid-19 and vaccination. BMJ medicine, 2(1), e000468. https://doi.org/10.1136/bmjmed-2022-000468
112. Washington-Brown, L., & Wimbish-Tompkins, R. (2021). Vaccines, Herd Immunity, and COVID-19. The ABNF journal: official journal of the Association of Black Nursing Faculty in Higher Education, Inc, 32(2), 42–46.
113. Wu, S. N., Xiao, T., Chen, H., & Li, X. H. (2024). Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition. RNA biology, 21(1), 1–18. https://doi.org/10.1080/15476286.2024.2433830
114. Yang, Y., Xiao, Z., Ye, K., He, X., Sun, B., Qin, Z., Yu, J., Yao, J., Wu, Q., Bao, Z., & Zhao, W. (2020). SARS-CoV-2: characteristics and current advances in research. Virology journal, 17(1), 117. https://doi.org/10.1186/s12985-020-01369-z
115. Yi, M., Li, T., Niu, M. et al. Targeting cytokine and chemokine signaling pathways for cancer

therapy. Sig Transduct Target Ther 9, 176 (2024). https://doi.org/10.1038/s41392-02401868-3

116. Yimga, J. (2024). Public health infrastructure and COVID-19 spread: An air transportation network analysis. Journal of the Air Transport Research Society, 3, 100040. https://doi.org/10.1016/j.jatrs.2024.100040
117. Yokota, S., Okabayashi, T., & Fujii, N. (2010). The battle between virus and host: modulation of Toll-like receptor signaling pathways by virus infection. Mediators of inflammation, 2010, 184328. https://doi.org/10.1155/2010/184328
118. Yu, S., Hu, H., Ai, Q., Bai, R., Ma, K., Zhou, M., & Wang, S. (2023). SARS-CoV-2 SpikeMediated Entry and Its Regulation by Host Innate Immunity. Viruses, 15(3), 639. https://doi.org/10.3390/v15030639
119. Yugar-Toledo, J. C., Yugar, L. B. T., Sedenho-Prado, L. G., Schreiber, R., & Moreno, H. (2023). Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations-a mini review. Frontiers in cardiovascular medicine, 10, 1162837. https://doi.org/10.3389/fcvm.2023.1162837
120. Zabidi, N. Z., Liew, H. L., Farouk, I. A., Puniyamurti, A., Yip, A. J. W., Wijesinghe, V. N., Low, Z. Y., Tang, J. W., Chow, V. T. K., & Lal, S. K. (2023). Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Viruses, 15(4), 944. https://doi.org/10.3390/v15040944
121. Zabidi, N. Z., Liew, H. L., Farouk, I. A., Puniyamurti, A., Yip, A. J. W., Wijesinghe, V. N., Low, Z. Y., Tang, J. W., Chow, V. T. K., & Lal, S. K. (2023). Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Viruses, 15(4), 944. https://doi.org/10.3390/v15040944
122. Zaidi, A. K., Bajpai, S., & Dehgani-Mobaraki, P. (2024). B cell responses to SARS-CoV-2. In A. K. Zaidi (Ed.), Progress in Molecular Biology and Translational Science (Vol. 202, pp. 155–181). Academic Press. https://doi.org/10.1016/bs.pmbts.2023.11.006
123. Zeng, H., Gao, X., Xu, G., Zhang, S., Cheng, L., Xiao, T., Zu, W., & Zhang, Z. (2022). SARSCoV-2 helicase NSP13 hijacks the host protein EWSR1 to promote viral replication by enhancing RNA unwinding activity. Infectious medicine, 1(1), 7–16. https://doi.org/10.1016/j.imj.2021.12.004
124. Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021). Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal transduction and targeted therapy, 6(1), 233. https://doi.org/10.1038/s41392-02100653-w
125. Zhang, Z., Nomura, N., Muramoto, Y., Ekimoto, T., Uemura, T., Liu, K., Yui, M., Kono, N., Aoki, J., Ikeguchi, M., Noda, T., Iwata, S., Ohto, U., & Shimizu, T. (2022). Structure of SARSCoV-2 membrane protein essential for virus assembly. Nature communications, 13(1), 4399. https://doi.org/10.1038/s41467-022-32019-3
126. Zhu, H., Wei, L. & Niu, P. The novel coronavirus outbreak in Wuhan, China. Glob health res policy 5, 6 (2020). https://doi.org/10.1186/s41256-020-00135-6

How to cite this article:

Bhanupratap Vishwakarma, Harshada Kulaye, Shruti Tiwari, Shizan Alam, Shivani Pandey and Sonali Joshi. 2025. SARS-CoV-2: A Comprehensive Review of Its Biology, Immunity, and Therapeutic Solutions. *Int.J.Curr.Microbiol.App.Sci.* 14(11): 101-134. **doi:** https://doi.org/10.20546/ijcmas.2025.1411.012